var title_f2_48_2816="Endometrial stripe normal";
var content_f2_48_2816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transvaginal sagittal image of a premenopausal normal uterus and cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 176px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The uterus is in the follicular phase of the menstrual cycle with a trilaminar appearance of the endometrium. The cervix is indicated by the long arrow. The short arrows demonstrated the correct placement of the calipers for assessing the thickness of the endometrial stripe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas D Shipp, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2816=[""].join("\n");
var outline_f2_48_2816=null;
var title_f2_48_2817="Garden type II hip fracture";
var content_f2_48_2817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Garden type II hip fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type II fractures are complete, but undisplaced. These rare fractures have a break in the trabeculations, but no shift in alignment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baumgaertner MR, Higgins TF. Femoral neck fractures. In: Rockwood and Green's Fractures in Adults, 5th ed, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2817=[""].join("\n");
var outline_f2_48_2817=null;
var title_f2_48_2818="Cryptogenic organizing pneumonia CT I";
var content_f2_48_2818=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptogenic organizing pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-resolution CT scan in cryptogenic organizing pneumonia. Asymmetric ground glass opacities are seen, with a predominantly peripheral distribution (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2818=[""].join("\n");
var outline_f2_48_2818=null;
var title_f2_48_2819="Amyloidosis tongue enlargement";
var content_f2_48_2819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79126&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Amyloidosis tongue enlargement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Physical examination showed an enlarged tongue protruding outside the mouth and showing scalloping of the lateral borders due to teeth indentations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Guijarro-Martinez R, Miragall Alba L, Villar Puchades R, et al. Rational management of macroglossia due to acquired systemic amyloidosis: does surgery play a role? J Oral Maxillofac Surg 2009; 67:2013. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2819=[""].join("\n");
var outline_f2_48_2819=null;
var title_f2_48_2820="Perianal abscess";
var content_f2_48_2820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perianal abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A perianal abscess is apparent as an erythematous, fluctuant bulge with surrounding edema.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David A Schwartz, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2820=[""].join("\n");
var outline_f2_48_2820=null;
var title_f2_48_2821="Budd-Chiari syndrome - medium power";
var content_f2_48_2821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Budd-Chiari syndrome (medium power, H&amp;E)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is drop-out of hepatocytes around a central vein and replacement by amorphous pale staining debris and red blood cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2821=[""].join("\n");
var outline_f2_48_2821=null;
var title_f2_48_2822="Ileal J pouch eversion";
var content_f2_48_2822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Ileal J pouch eversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows eversion of the ileal anal pouch and the mucosal lining on the outer surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2822=[""].join("\n");
var outline_f2_48_2822=null;
var title_f2_48_2823="Candidiasis of cord";
var content_f2_48_2823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidiasis of umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Gross candidiasis of umbilical cord; (B) Microscopic view of umbilical cord candidiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2823=[""].join("\n");
var outline_f2_48_2823=null;
var title_f2_48_2824="Treatment of female orgasmic disorder";
var content_f2_48_2824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of female orgasmic disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/48/2824/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/48/2824/contributors\">",
"     Andrea Bradford, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/48/2824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/48/2824/contributors\">",
"     Robert Segraves, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/48/2824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/48/2824/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/48/2824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H578730518\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female orgasmic disorder is characterized by a persistent or recurrent delay in or absence of orgasm following sexual arousal and adequate sexual stimulation. To diagnose female orgasmic disorder, the symptoms must cause marked distress or interpersonal difficulty [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment for female orgasmic disorder consists principally of education and psychosocial interventions, though clinical trials of their efficacy are limited.",
"   </p>",
"   <p>",
"    This topic discusses the treatment of female orgasmic disorder. The epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis of female orgasmic disorder are discussed separately. The assessment of patients with sexual dysfunction is also discussed separately. The epidemiology, risk factors, evaluation, and an overview of treatment of women with sexual dysfunction are also discussed separately. The prevalence and management of sexual dysfunction due to serotonergic antidepressants is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36600?source=see_link\">",
"     \"Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=see_link\">",
"     \"The sexual history and approach to the patient with sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link\">",
"     \"Sexual dysfunction in women: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=see_link&amp;anchor=H2#H2\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\", section on 'Management of sexual dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121973732\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female orgasmic disorder may be lifelong or acquired, generalized (occurring in all situations) or situational (occurring in select situations). An example of the situational type of the disorder is a woman who has orgasms through masturbation but not during partnered sexual activity",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121973788\">",
"    <span class=\"h2\">",
"     Primary female orgasmic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with primary female orgasmic disorder have not previously experienced orgasm in any situation. Other terms used synonymously include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;Lifelong generalized female orgasmic disorder&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Primary anorgasmia&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Preorgasmic&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121973817\">",
"    <span class=\"h2\">",
"     Secondary female orgasmic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with secondary female orgasmic disorder have previously been orgasmic but present with current orgasmic dysfunction. As examples, this category would include women who were once orgasmic but not any longer (generalized) as well as women who are orgasmic through masturbation but not partnered sexual activity (situational).",
"   </p>",
"   <p>",
"    Other terms used synonymously include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &ldquo;Situational orgasmic disorder&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Acquired orgasmic disorder&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578730963\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;General principles in the management of female orgasmic disorder include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establishing a collaborative relationship with the patient",
"     </li>",
"     <li>",
"      Gathering an adequate psychosexual history to establish probable causal or contributing factors",
"     </li>",
"     <li>",
"      Setting clear, feasible treatment goals",
"     </li>",
"     <li>",
"      Ensuring that the patient&rsquo;s mood and psychosocial functioning are stable. Although the patient may prioritize concerns with sexual functioning, problems such as serious mood disturbance, psychotic symptoms, suicidality, and pervasive relational conflict should be treated prior to focusing clinical attention on female orgasmic disorder.",
"     </li>",
"     <li>",
"      The nature of most treatments necessitate that patients complete assigned readings, exercises, or activities between clinician visits. Adherence to treatment recommendations, in our experience, contributes to positive outcomes. Clinicians should help patients maintain motivation and resolve barriers to adherence [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578730970\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education should precede and support a discussion of treatment options. Women typically welcome accurate, detailed information about anatomy and sexual function. The process of educating the patient will at times reveal assumptions or misconceptions that may be contributing to a problem. Receipt of corrective information is often therapeutic. Further assessment of contributing factors (eg, relationship problems, negative beliefs about sexuality) can often be conducted during education. The patient should understand the rationale for the proposed treatment and the necessity of her taking an active role in treatment. Motivated, high functioning patients may benefit from an accurate self-help book with little or no additional intervention by the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/4\">",
"     4",
"    </a>",
"    ]. An excellent resource is the self-help manual",
"    <em>",
"     Becoming Orgasmic",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/5\">",
"     5",
"    </a>",
"    ]",
"    <em>",
"     .",
"    </em>",
"   </p>",
"   <p>",
"    The clinician should have a frank discussion with the patient about the adequacy of stimulation that she receives. Women and their partners may benefit from information about sexual positions and techniques to enhance the woman&rsquo;s sexual stimulation. If the woman engages in vaginal intercourse with a male partner, use of the coital alignment technique has been shown to facilitate orgasm and satisfaction with sexual activity. The coital alignment technique is a variant of the missionary position in which the male partner positions himself higher in relation to the female&rsquo;s body and uses a downward (rather than horizontal) thrusting motion, allowing the base and dorsal side of the penis to come into closer contact with the clitoris. This allows for greater clitoral stimulation and, hypothetically, a greater likelihood of orgasm stimulated through vaginal intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attainment of orgasm through vaginal intercourse may not be an achievable goal in some patients. Clinicians should discuss manual and oral stimulation as normal, legitimate means of attaining orgasm during partnered sexual activity.",
"   </p>",
"   <p>",
"    Some women will benefit substantially from a single encounter that involves validation, education, and an opportunity to ask questions. However, in our experience, many women present for treatment after multiple failed attempts to remedy the problem on their own and require further treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578730977\">",
"    <span class=\"h1\">",
"     PSYCHOSOCIAL INTERVENTION STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of psychosocial interventions, also referred to as &ldquo;sex therapy techniques,&rdquo; make up the vast majority of the empirical literature on treatments for female orgasmic disorder. Most of the interventions that have been examined empirically are grounded in behavior therapy principles, with considerable overlap among the approaches. They share an emphasis on exposure to novel experiences and information, learning new skills, and generalization of these skills to a range of sexual activities. In clinical practice, these interventions are frequently combined or coupled with other treatments (eg, marital therapy) for women with more complex presentations, or if monotherapy is not successful.",
"   </p>",
"   <p>",
"    Clinical trials of these interventions are limited, with small sample sizes and few head-to-head comparisons. In our experience, women with primary female orgasmic disorder can often be effectively treated with psychosocial interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/9\">",
"     9",
"    </a>",
"    ]. Women with acquired or situational female orgasmic disorder are less likely to benefit from sex therapy, especially in the long term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36600?source=see_link&amp;anchor=H12710909#H12710909\">",
"     \"Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link&amp;anchor=H20#H20\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychosocial interventions are described below, followed by data on their efficacy. Where available, data from trials in primary female orgasmic disorder are described first, followed by data in secondary female orgasmic disorder, and then by data in samples including both disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578730984\">",
"    <span class=\"h2\">",
"     Directed masturbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Directed masturbation (sometimes referred to as masturbation training) is a program of education and self-awareness exercises aimed at teaching a woman to reach orgasm through self-stimulation and, eventually, through partnered sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. After the rationale has been explained and the woman is educated about basic sexual anatomy and physiology, she is instructed to explore her body visually and through touch in a series of exercises at home.",
"   </p>",
"   <p>",
"    The initial goal is simply to become familiar with one&rsquo;s own body, particularly the genitals. In later steps the focus is to identify areas that are pleasurable to touch, and then to stimulate those areas directly. Erotic videos, pictures, or text,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a vibrator can be used to enhance this experience. Once a woman is able to reach orgasm reliably, the partner (if applicable) is brought into the home &ldquo;practice&rdquo; sessions so that he or she can learn to stimulate the woman to orgasm during sexual activity.",
"   </p>",
"   <p>",
"    Clinicians teach directed masturbation in individual, group, and couples formats [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The techniques can be learned in a self-help format, eg, with the manual",
"    <em>",
"     Becoming Orgasmic",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/4\">",
"     4",
"    </a>",
"    ], although the efficacy of a self-help approach (without clinician assistance) has not been evaluated.",
"   </p>",
"   <p>",
"    Based on our clinical experience, weekly sessions on directed masturbation over a period of five to six weeks are likely to be acceptable and efficacious for most patients, even though clinical trials often studied twice weekly sessions over this period, or weekly sessions over a longer duration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/14\">",
"     14",
"    </a>",
"    ]. Highly motivated patients may be able to benefit with less frequent contact (eg, semi-monthly sessions), particularly after the first several weeks of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H121973880\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three small randomized trials found that directed masturbation led to better outcomes than other interventions or control conditions in women with primary female orgasmic disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial compared a 12-session directed masturbation intervention to a 12-session treatment that included psychoeducation and sensate focus exercises in 37 women with primary female orgasmic disorder and their male partners [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/15\">",
"       15",
"      </a>",
"      ]. At the end of treatment, more women in the directed masturbation group were able to experience orgasm compared to the",
"      <span class=\"nowrap\">",
"       education/sensate",
"      </span>",
"      focus group (90 versus 53 percent). At one year, the women in the directed masturbation group maintained treatment gains.",
"     </li>",
"     <li>",
"      Sixty women with primary female orgasmic disorder were randomly assigned to one of two self-administered directed masturbation treatments or a waitlist control condition [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/4\">",
"       4",
"      </a>",
"      ]. Treatment groups were split between those who received instructions in writing or in a series of videotapes. Participants in both directed masturbation groups were provided a vibrator. Many more of the 40 women assigned to one of the directed masturbation groups experienced orgasm by the end of treatment compared to the women in the control group (60 versus 0 percent). There were no significant differences in outcomes between written and video treatment groups.",
"     </li>",
"     <li>",
"      Thirty women with primary female orgasmic disorder accompanied by sexual anxiety or aversion were randomly assigned to receive directed masturbation, systematic desensitization, or to the waiting list control [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/13\">",
"       13",
"      </a>",
"      ]. Sexual arousal and orgasm increased among women in the directed masturbation and waiting list groups compared to the group receiving systematic desensitization.",
"     </li>",
"     <li>",
"      In a mixed sample consisting of 11 women, three with primary female orgasmic disorder and eight with secondary (acquired or situational) female orgasmic disorder, a seven-week, randomized trial compared a directed masturbation program to a waitlist control supplemented by written educational information [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/16\">",
"       16",
"      </a>",
"      ]. Women in the directed masturbation group experienced more frequent coital orgasms at the end of treatment than the control group; their gains were enhanced six weeks post-treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9817026\">",
"    <span class=\"h2\">",
"     Sensate focus exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensate focus is a couples-oriented treatment that consists of clinician visits for education and treatment planning, and a series of home exercises to increase the partners&rsquo; comfort with sexual intimacy and reduce avoidance of feared experiences. One goal of sensate focus is to orient the partners&rsquo; goals for sex toward attaining sensual pleasure rather than orgasm per se [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensate focus exercises usually begin by having partners exchange pleasurable touch of areas of the body other than the genitals and breasts, perhaps even while clothed. Subsequent sessions gradually allow for greater touching of breasts, buttocks, and eventually genitals, although intercourse is not recommended until the final stages of treatment.",
"   </p>",
"   <p>",
"    The therapist typically helps the couple enhance verbal and nonverbal sexual communication skills so that the partners can be enabled to give guidance and feedback to one another regarding their preferences for touch. Barriers to regular, open sexual expression (eg, repeatedly &ldquo;forgetting&rdquo; to complete exercises, negative feelings arising during exercises) are also commonly addressed in treatment.",
"   </p>",
"   <p>",
"    Sensate focus training is typically provided in 10 to 16 sessions, occurring weekly or biweekly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136202569\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single, small randomized trial found sensate focus exercises less effective than directed masturbation in primary female orgasmic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/15\">",
"     15",
"    </a>",
"    ]. The trial compared a 12-session treatment that included psychoeducation and sensate focus exercises to a directed masturbation intervention in 37 women and their male partners. A smaller proportion of women in the",
"    <span class=\"nowrap\">",
"     education/sensate",
"    </span>",
"    focus group compared to the directed masturbation group were able to experience orgasm at the end of the trial (53 versus 90 percent).",
"   </p>",
"   <p>",
"    Two small trials of a sensate focus intervention in women with secondary orgasmic disorder found mixed evidence for improving orgasmic function. Improvement was seen in secondary outcomes, including relationship satisfaction and enjoyment of noncoital sexual activity.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A trial randomly assigned 48 women with secondary orgasmic disorder and their partners to either a waitlist control condition or to one of three 12-session treatments: sensate focus, systematic desensitization, or combined systematic desensitization and sensate focus [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/18\">",
"       18",
"      </a>",
"      ]. Outcomes were reported in terms of a score on a measure of &ldquo;sexual motivation&rdquo;; data on orgasmic frequency before and after treatment were not provided. Outcomes for the two monotherapy groups were comparable and superior compared to the control condition, in which no improvement was observed. Combined treatment was found to be inferior to monotherapy. Gains in the sensate focus group were not maintained at six months follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a 14-week uncontrolled trial of sensate focus exercises in 23 women with secondary female orgasmic dysfunction and their spouses, no improvement was seen in orgasmic functioning [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/19\">",
"       19",
"      </a>",
"      ]. Subjects reported increased enjoyment of noncoital sexual activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14777000\">",
"    <span class=\"h2\">",
"     Cognitive-behavioral sex therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral sex therapy combines behavioral techniques such as directed masturbation and sensate focus with cognitive techniques with which the clinician helps the patient to identify and challenge distorted beliefs and assumptions that may interfere with sexual pleasure. (See",
"    <a class=\"local\" href=\"#H578730984\">",
"     'Directed masturbation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9817026\">",
"     'Sensate focus exercises'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Examples of beliefs and assumptions that are addressed include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fear of experiencing orgasm in front of a partner (eg, difficulty in acting spontaneously out of concern for losing control or having her behavior perceived negatively during orgasm)",
"     </li>",
"     <li>",
"      Unrealistic expectations for sexual performance",
"     </li>",
"     <li>",
"      Excessive concern about appearance and attractiveness during sexual activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapeutic activities may include cognitive restructuring (systematically identifying and correcting logical errors that maintain dysfunctional beliefs) and behavioral experiments in which the patient &ldquo;tests&rdquo; her beliefs, usually in the context of real-life situations. As an example, a woman who is accustomed to using fantasy during masturbation may find herself avoiding fantasy during sexual activity with a new partner due to the belief that it will lead her to desire her partner less. Once given &ldquo;permission&rdquo; to engage in fantasy to reach orgasm during sex, she may find that she more often looks forward to lovemaking and may even experience orgasm without the use of fantasy in the future.",
"   </p>",
"   <p>",
"    Cognitive-behavioral sex therapy also generally incorporates specific skills such as partner communication training, which may help in modifying thoughts and behaviors that might contribute to the problem.",
"   </p>",
"   <p>",
"    Cognitive-behavioral sex therapy is typically provided to women or couples in 10 to 15 weekly or biweekly sessions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136202406\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral sex therapy has not been studied in randomized trials in women with female orgasmic disorder. Three small uncontrolled trials in couples with mixed sexual dysfunction found improvement in orgasmic functioning following treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twelve women with primary anorgasmia and their partners, taking part in a larger trial, received a 20-session intervention employing CBT strategies [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/20\">",
"       20",
"      </a>",
"      ]. Treatment focused on education, anxiety reduction, communication and assertiveness training, correction of maladaptive beliefs, and, in some cases, masturbation training. In the period following treatment, 22 percent were able to have an orgasm in at least 50 percent of partnered sexual encounters. No subjects met this criterion in a follow-up assessment several months later.",
"     </li>",
"     <li>",
"      Thirty-five women with primary or secondary orgasmic disorder and their spouses, taking part in a larger trial of persons with mixed sexual disorders, were treated with cognitive-behavioral sex therapy techniques weekly for 15 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/21\">",
"       21",
"      </a>",
"      ]. Women with primary orgasmic disorder reported increased frequency of orgasm with masturbation post-treatment (from 0 to 25 percent of the time) and more so at three months follow-up (50 percent of the time); however, these gains did not apply to orgasm with other forms of stimulation. Women with secondary orgasmic disorder reported increased frequency of orgasm during four of five sexual activities assessed, including masturbation and noncoital sexual activity.",
"     </li>",
"     <li>",
"      In an uncontrolled trial, 54 women with mixed sexual dysfunctions were treated with cognitive-behavioral sex therapy. The proportion of women in the sample with anorgasmia decreased from pre- to post-treatment (67 versus 11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14777046\">",
"    <span class=\"h2\">",
"     Systematic desensitization and exposure therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with orgasmic dysfunction accompanied by anxiety associated with partnered sexual activity aims to increase the patient&rsquo;s comfort with these activities and reduce avoidance of feared experiences.",
"   </p>",
"   <p>",
"    Systematic desensitization is an anxiety reduction technique that is based on the principles of conditioning. An anxiety provoking stimulus (which may be real or imagined) is paired with a relaxation response until the stimulus no longer evokes anxiety. As treatment progresses, the woman is assisted to extinguish her anxiety response to increasingly challenging scenarios that are relevant to her sexual life. The patient is first asked to construct a list of progressively anxiety provoking scenarios that are personally relevant (eg, having breasts touched while clothed, being seen in the nude, receiving manual clitoral stimulation) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/23\">",
"     23",
"    </a>",
"    ]. She is then taught relaxation techniques such as diaphragmatic breathing and progressive muscle relaxation that are conducted while experiencing these scenarios, usually through imaginal or verbal exposure.",
"   </p>",
"   <p>",
"    Starting with the least challenging scenario, the patient imagines or verbally describes the scenario and applies relaxation skills when she notices anxiety. This process is repeated until the scenario no longer provokes an anxious response, at which point the patient progresses to the next most anxiety provoking item on the hierarchy. Related anxiety reduction techniques that may be used similarly include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In vivo desensitization, which closely resembles sensate focus exercises but with more explicit attention to anxiety",
"     </li>",
"     <li>",
"      Imaginal exposure without the use of relaxation techniques, in which case habituation and cognitive processing are the presumed mediators of anxiety reduction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343899501\">",
"    <span class=\"h3\">",
"     Exposure therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In practice, systematic desensitization is seldom used as a first-line intervention for anxiety, having been replaced over time by more effective and efficient exposure-based treatments. Exposure therapies preserve some elements of systematic desensitization (chiefly, constructing and working through a hierarchy of anxiety-provoking scenarios) but do not rely on the use of relaxation techniques and generally involve greater attention to cognitive factors. Anxiety reduction techniques are usually incorporated with other interventions for treatment of female orgasmic disorder and are generally limited to situations in which sexual anxiety is believed to contribute substantially to the problem.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136202700\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small randomized trials of systematic desensitization in women with primary or secondary female orgasmic disorder found positive results, but one did not report the intervention&rsquo;s effect on orgasmic functioning.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty women with primary female orgasmic disorder accompanied by sexual anxiety or aversion were randomly assigned to receive systematic desensitization, directed masturbation, or to the waiting list control [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/13\">",
"       13",
"      </a>",
"      ]. After the intervention, sexual arousal and orgasm increased among women in the directed masturbation and waiting list groups compared to the group receiving systematic desensitization.",
"     </li>",
"     <li>",
"      A trial randomly assigned 48 women with secondary orgasmic dysfunction and their partners to either a waitlist control condition or to one of three 12-session treatments: sensate focus, systematic desensitization, or combined systematic desensitization and sensate focus intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/18\">",
"       18",
"      </a>",
"      ]. Outcomes were reported in terms of a score on a measure of &ldquo;sexual motivation&rdquo;; data on orgasmic frequency before and after treatment were not provided. Outcomes for the two monotherapy groups were comparable and superior to the control condition, in which no improvement was observed. Combined therapy was found to be inferior to monotherapy. Gains were maintained in the systematic desensitization group at six-month follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H136202620\">",
"    <span class=\"h2\">",
"     Other psychosocial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other treatments that have been tested in female orgasmic disorder include integrative psychosocial treatments that combine treatment modalities drawing on multiple theoretical perspectives [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. As an example, a trial of 26 women with female orgasmic disorder compared an integrative treatment that included behavioral, psychoanalytic, and hypnosis components, delivered three times per week for 42 weeks, to a 16-week behavioral intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/17\">",
"     17",
"    </a>",
"    ], to a control condition [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/24\">",
"     24",
"    </a>",
"    ]. Immediately following their respective treatments, a greater proportion of women receiving the integrative intervention achieved the desired outcome criterion of achieving orgasm during at least 60 percent of occasions of foreplay or intercourse compared to women in the behavioral group or the control group (88 versus 25 versus percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578731040\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of psychosocial interventions for female orgasmic disorder requires specialized training beyond that generally received by most types of mental health clinicians. Several professional organizations have membership directories that can be used to locate a specialist in sexual disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Society for Sex Therapy and Research (",
"      <a class=\"external\" href=\"file://www.sstarnet.org/\">",
"       www.sstarnet.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      American Association of Sexuality Educators, Counselors, and Therapists (",
"      <a class=\"external\" href=\"file://www.aasect.org/\">",
"       www.aasect.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      International Society for the Study of Women&rsquo;s Sexual Health (",
"      <a class=\"external\" href=\"file://www.isswsh.org/\">",
"       www.isswsh.org",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578731047\">",
"    <span class=\"h1\">",
"     MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no published randomized trials of medication for primary female orgasmic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic treatment of secondary orgasmic dysfunction induced by serotonergic antidepressants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=see_link\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578731054\">",
"    <span class=\"h1\">",
"     OTHER INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1767779\">",
"    <span class=\"h2\">",
"     Kegel exercises",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kegel exercises, which strengthen the pubococcygeal muscles, have been proposed as a means for women to enhance orgasm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/26\">",
"     26",
"    </a>",
"    ]; however, limited evidence from two small randomized trials does not support their use for female orgasmic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2824/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of pelvic floor muscle training postpartum for incontinence, and in women with pelvic organ prolapse is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of urinary incontinence\", section on 'Pelvic muscle exercises'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4857?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations, diagnosis, and nonsurgical management of posterior vaginal defects\", section on 'Pelvic floor muscle training'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1767786\">",
"    <span class=\"h2\">",
"     Genital cosmetic procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marketing materials for genital cosmetic procedures occasionally make claims about enhancing orgasm. However, there is no credible scientific evidence supporting the efficacy in orgasmic dysfunction of collagen injection for &ldquo;G-spot augmentation&rdquo;, clitoral hood reduction, or any other vulvovaginal cosmetic procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14777763\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of treatment for female orgasmic disorder should be based on features of the patient&rsquo;s presentation, including situations in which dysfunction occurs, on the basis of the presumed etiology of the disorder, and any anticipated difficulties with acceptance or adherence to treatment The recommendations that follow are largely based on our clinical experience and supported in some cases by small clinical trials of mostly limited methodological quality. Larger randomized trials and head-to-head comparisons of interventions are needed to guide choices among treatments.",
"   </p>",
"   <p>",
"    Patient education should be provided to women with female orgasmic disorder, preceding and supporting a discussion about treatment options. Detailed information about anatomy and sexual function can correct misconceptions that may be contributing to a problem. (See",
"    <a class=\"local\" href=\"#H578730970\">",
"     'Patient education'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women with primary female orgasmic disorder, we suggest treatment with directed masturbation as a first-line therapy over other interventions. (See",
"    <a class=\"local\" href=\"#H578730984\">",
"     'Directed masturbation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with primary female orgasmic disorder and significant anxiety about sexual activity with a partner, we suggest supplementing directed masturbation with sensate focus exercises. Exposure therapy may be a useful adjunct to treatment in cases where sensate focus exercises are ineffective or substitution in cases where anxiety is exacerbated. (See",
"      <a class=\"local\" href=\"#H9817026\">",
"       'Sensate focus exercises'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14777046\">",
"       'Systematic desensitization and exposure therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with primary female orgasmic disorder in which distorted negative beliefs contribute to orgasm problems, we suggest supplementing directed masturbation with more explicit cognitive-behavioral therapy strategies. (See",
"      <a class=\"local\" href=\"#H14777000\">",
"       'Cognitive-behavioral sex therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women who can have orgasms through masturbation but not during partnered sexual activity (ie, situational secondary female orgasmic disorder), we suggest education about sexual positions and activities to enhance clitoral stimulation. Treatment of the couple with cognitive-behavioral sex therapy can be helpful in cases that do not respond adequately to education alone. The clinician should provide education to both partners and pay careful attention to potential interpersonal conflicts that might maintain the problem or reduce motivation to resolve it. (See",
"    <a class=\"local\" href=\"#H578730970\">",
"     'Patient education'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14777000\">",
"     'Cognitive-behavioral sex therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For women who have orgasmic problems associated with relationship difficulties that extend beyond sexual issues, we suggest treatment with couples therapy in addition to sex therapy. Couples therapy can be useful prior to sex therapy or as an integrated intervention.",
"   </p>",
"   <p>",
"    Acquired female orgasmic disorder generally requires treatment directed at the apparent etiology of the dysfunction or contributing factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36600?source=see_link&amp;anchor=H12710909#H12710909\">",
"     \"Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link&amp;anchor=H20#H20\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Diagnostic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=see_link\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H578731481\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient education should be provided to women with female orgasmic disorder, preceding and supporting a discussion about treatment options. Detailed information about anatomy and sexual function can correct misconceptions that may be contributing to a problem. (See",
"      <a class=\"local\" href=\"#H578730970\">",
"       'Patient education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most women with primary female orgasmic disorder, we suggest treatment with directed masturbation as a first-line therapy over other interventions (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This intervention involves education and training in self-awareness exercises. (See",
"      <a class=\"local\" href=\"#H578730984\">",
"       'Directed masturbation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with primary female orgasmic disorder and significant anxiety about sexual activity with a partner, we suggest supplementing directed masturbation with sensate focus exercises (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Adjunctive exposure therapy is a reasonable alternative in cases where sensate focus exercises are ineffective or exacerbate anxiety. (See",
"      <a class=\"local\" href=\"#H9817026\">",
"       'Sensate focus exercises'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14777046\">",
"       'Systematic desensitization and exposure therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with primary female orgasmic disorder in which distorted negative beliefs contribute to orgasm problems, we suggest supplementing directed masturbation with more explicit cognitive-behavioral therapy strategies. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H14777000\">",
"       'Cognitive-behavioral sex therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with female orgasmic disorder who can have orgasms through masturbation but not during partnered sexual activity, education about sexual positions and activities to enhance clitoral stimulation can be helpful. If this does not lead to a satisfactory outcome, cognitive-behavioral sex therapy can be used for the couple (the patient and her partner). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), Fourth edition, Text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/2\">",
"      Sarwer DB, Durlak JA. A field trial of the effectiveness of behavioral treatment for sexual dysfunctions. J Sex Marital Ther 1997; 23:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/3\">",
"      Hawton K, Catalan J. Prognostic factors in sex therapy. Behav Res Ther 1986; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/4\">",
"      McMullen S, Rosen RC. Self-administered masturbation training in the treatment of primary orgasmic dysfunction. J Consult Clin Psychol 1979; 47:912.",
"     </a>",
"    </li>",
"    <li>",
"     Heiman JR, LoPiccolo J. Becoming Orgasmic: A sexual and personal growth program for women, revised and expanded edition, Simon &amp; Schuster, New York 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/6\">",
"      Pierce AP. The coital alignment technique (CAT): an overview of studies. J Sex Marital Ther 2000; 26:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/7\">",
"      Hurlbert DF, Apt C. The coital alignment technique and directed masturbation: a comparative study on female orgasm. J Sex Marital Ther 1995; 21:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/8\">",
"      Eichel EW, Eichel JD, Kule S. The technique of coital alignment and its relation to female orgasmic response and simultaneous orgasm. J Sex Marital Ther 1988; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/9\">",
"      Meston CM, Levin RJ, Sipski ML, et al. Women's orgasm. Annu Rev Sex Res 2004; 15:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/10\">",
"      Charles Lobitz W, LoPiccolo J. New methods in the behavioral treatment of sexual dysfunction. J Behav Ther Exp Psychiatry 1972; 3:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/11\">",
"      LoPiccolo J, Lobitz WC. The role of masturbation in the treatment of orgasmic dysfunction. Arch Sex Behav 1972; 2:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/12\">",
"      Barbach LG. Group treatment of preorgasmic women. J Sex Marital Ther 1974; 1:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/13\">",
"      Andersen BL. A comparison of systematic desensitization and directed masturbation in the treatment of primary orgasmic dysfunction in females. J Consult Clin Psychol 1981; 49:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/14\">",
"      Morokoff PJ, LoPiccolo J. A comparative evaluation of minimal therapist contact and 15-session treatment for female orgasmic dysfunction. J Consult Clin Psychol 1986; 54:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/15\">",
"      Riley AJ, Riley EJ. A controlled study to evaluate directed masturbation in the management of primary orgasmic failure in women. Br J Psychiatry 1978; 133:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/16\">",
"      Dodge LJ, Glasgow RE, O'Neill HK. Bibliotherapy in the treatment of female orgasmic dysfunction. J Consult Clin Psychol 1982; 50:442.",
"     </a>",
"    </li>",
"    <li>",
"     Masters WH, Johnson VE. Human Sexual Inadequacy, Little, Brown, Boston 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/18\">",
"      Everaerd W, Dekker J. Treatment of secondary orgasmic dysfunction: a comparison of systematic desensitization and sex therapy. Behav Res Ther 1982; 20:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/19\">",
"      Fichten CS, Libman E, Brender W. Methodological issues in the study of sex therapy: effective components in the treatment of secondary orgasmic dysfunction. J Sex Marital Ther 1983; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/20\">",
"      Munjack D, Cristol A, Goldstein A, et al. Behavioural treatment of orgasmic dysfunction: a controlled study. Br J Psychiatry 1976; 129:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/21\">",
"      LoPiccolo J, Heiman JR, Hogan DR, Roberts CW. Effectiveness of single therapists versus cotherapy teams in sex therapy. J Consult Clin Psychol 1985; 53:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/22\">",
"      McCabe MP. Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J Sex Marital Ther 2001; 27:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/23\">",
"      Husted JR. Desensitization procedures in dealing with female sexual dysfunction. Couns Psychol 1975; 5:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/24\">",
"      Obler M. A comparison of a hypnoanalytic/behavior modification technique and a cotherapist-type treatment with primary orgasmic dysfunction females: some preliminary results. J Sex Res 1982; 18:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/25\">",
"      Kilmann PR, Milan RJ Jr, Boland JP, et al. The treatment of secondary orgasmic dysfunction II. J Sex Marital Ther 1987; 13:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/26\">",
"      KEGEL AH. Sexual functions of the pubococcygeus muscle. West J Surg Obstet Gynecol 1952; 60:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/27\">",
"      Chambless DL, Sultan FE, Stern TE, et al. Effect of pubococcygeal exercise on coital orgasm in women. J Consult Clin Psychol 1984; 52:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2824/abstract/28\">",
"      Roughan PA, Kunst L. Do pelvic floor exercises really improve orgasmic potential? J Sex Marital Ther 1981; 7:223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83693 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2824=[""].join("\n");
var outline_f2_48_2824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H578731481\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H578730518\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H121973732\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H121973788\">",
"      Primary female orgasmic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H121973817\">",
"      Secondary female orgasmic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H578730963\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H578730970\">",
"      PATIENT EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H578730977\">",
"      PSYCHOSOCIAL INTERVENTION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H578730984\">",
"      Directed masturbation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H121973880\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9817026\">",
"      Sensate focus exercises",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H136202569\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14777000\">",
"      Cognitive-behavioral sex therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H136202406\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14777046\">",
"      Systematic desensitization and exposure therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H343899501\">",
"      - Exposure therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H136202700\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H136202620\">",
"      Other psychosocial interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H578731040\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H578731047\">",
"      MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H578731054\">",
"      OTHER INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1767779\">",
"      Kegel exercises",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1767786\">",
"      Genital cosmetic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14777763\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H578731481\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4857?source=related_link\">",
"      Clinical manifestations, diagnosis, and nonsurgical management of posterior vaginal defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36600?source=related_link\">",
"      Female orgasmic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42904?source=related_link\">",
"      The sexual history and approach to the patient with sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=related_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_48_2825="Epoetin alfa: Drug information";
var content_f2_48_2825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epoetin alfa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/12/25797?source=see_link\">",
"    see \"Epoetin alfa: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=see_link\">",
"    see \"Epoetin alfa: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epogen&reg;;",
"     </li>",
"     <li>",
"      Procrit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eprex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Colony Stimulating Factor;",
"     </li>",
"     <li>",
"      Erythropoiesis-Stimulating Agent (ESA);",
"     </li>",
"     <li>",
"      Growth Factor;",
"     </li>",
"     <li>",
"      Recombinant Human Erythropoietin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anemia associated with chronic kidney disease:",
"     </b>",
"     Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic kidney disease patients",
"     </i>",
"     <b>",
"      <i>",
"       ON dialysis",
"      </i>",
"     </b>",
"     (I.V. route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL): I.V., SubQ: Initial dose: 50-100 units/kg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic kidney disease patients",
"     </i>",
"     <b>",
"      <i>",
"       NOT on dialysis",
"      </i>",
"     </b>",
"     (consider initiating treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 10 g/dL): I.V., SubQ: Initial dose: 50-100 units/kg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustments for chronic kidney disease patients (either on dialysis or not on dialysis):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain a Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anemia due to chemotherapy in cancer patients:",
"     </b>",
"     Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is &ge;2 months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Discontinue erythropoietin following completion of chemotherapy. SubQ: Initial dose: 150 units/kg 3 times/week or 40,000 units once weekly until completion of chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustments:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin does not increase by &gt;1 g/dL",
"     <b>",
"      and",
"     </b>",
"     remains below 10 g/dL after initial 4 weeks: Increase to 300 units/kg 3 times/week or 60,000 units weekly; discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin exceeds a level needed to avoid red blood cell transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period",
"     <b>",
"      or",
"     </b>",
"     hemoglobin reaches a level sufficient to avoid red blood cell transfusion: Reduce dose by 25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anemia due to zidovudine in HIV-infected patients:",
"     </b>",
"     Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Hemoglobin levels should not exceed 12 g/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum erythropoietin levels &le;500 mUnits/mL and zidovudine doses &le;4200 mg/week): I.V., SubQ: Initial: 100 units/kg 3 times/week; if hemoglobin does not increase after 8 weeks, increase dose by ~50-100 units/kg at 4-8 week intervals until hemoglobin reaches a level sufficient to avoid RBC transfusion; maximum dose: 300 units/kg. Withhold dose if hemoglobin exceeds 12 g/dL, may resume treatment with a 25% dose reduction once hemoglobin &lt;11 g/dL. Discontinue if hemoglobin increase is not achieved with 300 units/kg for 8 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Surgery patients",
"     </b>",
"     (perioperative hemoglobin should be &gt;10 g/dL and &le;13 g/dL; DVT prophylactic anticoagulation is recommended): SubQ: Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 units/kg/day beginning 10 days before surgery, on the day of surgery, and for 4 days after surgery",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 units/kg once weekly for 4 doses, given 21- , 14-, and 7 days before surgery, and on the day of surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Symptomatic anemia associated with myelodysplastic syndrome (unlabeled use):",
"     </b>",
"     SubQ: 40,000-60,000 units 1-3 times/week (NCCN MDS guidelines v.2.2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F165789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=see_link\">",
"      see \"Epoetin alfa: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anemia associated with chronic kidney disease (CKD):",
"     </b>",
"     Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Chronic kidney disease patients",
"     </i>",
"     <b>",
"      <i>",
"       ON dialysis",
"      </i>",
"     </b>",
"     (I.V. route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1 month to 16 years: I.V., SubQ: Initial dose: 50 units/kg 3 times/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustments for chronic kidney disease patients:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain a Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anemia due to chemotherapy in cancer patients:",
"     </b>",
"     Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is &ge;2 months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Discontinue erythropoietin following completion of chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children &ge;5 years: I.V.: Initial dose: 600 units/kg once weekly until completion of chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dosage adjustments:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin does not increase by &gt;1 g/dL",
"     <b>",
"      and",
"     </b>",
"     remains &lt;10 g/dL after initial 4 weeks: Increase to 900 units/kg (maximum dose: 60,000 units); discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin exceeds a level needed to avoid red blood cell transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If hemoglobin increases &gt;1 g/dL in any 2-week period",
"     <b>",
"      or",
"     </b>",
"     hemoglobin reaches a level sufficient to avoid red blood cell transfusion: Reduce dose by 25%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anemia due to zidovudine in HIV-infected patients:",
"     </b>",
"     Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Hemoglobin levels should not exceed 12 g/dL. Children 8 months to 17 years (based on limited data): I.V., SubQ: Reported dosing range: 50-400 units/kg 2-3 times/week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epogen&reg;: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains albumin (human), benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procrit&reg;: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains albumin (human), benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epogen&reg;: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL) [contains albumin (human)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procrit&reg;: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL); 40,000 units/mL (1 mL) [contains albumin (human)]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10533184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eprex&reg;: 1000 units/0.5 mL (0.5 mL), 2000 units/0.5 mL (0.5 mL), 3000 units/0.3 mL (0.3 mL), 4000 units/0.4 mL (0.4 mL), 5000 units/0.5 mL (0.5 mL), 6000 units/0.6 mL (0.6 mL), 8000 units/0.8 mL (0.8 mL), 10,000 units/mL (1 mL), 20,000 units/0.5 mL (0.5 mL), 30,000 units/0.75 mL (0.75 mL), 40,000 units/mL (1 mL) [contains polysorbate 80; prefilled syringe, free of human serum albumin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Healthcare providers and hospitals must be enrolled in the ESA APPRISE (Assisting Providers and Cancer Patients with Risk Information for the Safe use of ESAs) Oncology Program (866-284-8089; file://www.esa-apprise.com) to prescribe or dispense ESAs (ie, epoetin alfa, darbepoetin alfa) to patients with cancer.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Epogen&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM088591.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM088591.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Procrit&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM088988.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM088988.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F165742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ is the preferred route of administration",
"     <b>",
"      except",
"     </b>",
"     in patients with CKD on hemodialysis; 1:1 dilution with bacteriostatic NS (containing benzyl alcohol) acts as a local anesthetic to reduce pain at the injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patients with CKD on hemodialysis: I.V. route preferred; it may be administered into the venous line at the end of the dialysis procedure",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F165816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      10",
"     </sub>",
"     W with albumin 0.05%, D",
"     <sub>",
"      10",
"     </sub>",
"     W with albumin 0.1%;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      10",
"     </sub>",
"     W with albumin 0.01%, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in TPN.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of anemia due to concurrent myelosuppressive chemotherapy in patients with cancer (nonmyeloid malignancies) receiving chemotherapy (palliative intent) for a planned minimum of 2 additional months of chemotherapy; treatment of anemia due to chronic kidney disease (including patients on dialysis and not on dialysis) to decrease the need for RBC transfusion; treatment of anemia associated with HIV (zidovudine) therapy when endogenous erythropoietin levels &le;500 mUnits/mL; reduction of allogeneic RBC transfusion for elective, noncardiac, nonvascular surgery when perioperative hemoglobin is &gt;10 to &le;13 g/dL and there is a  high risk for blood loss",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Epoetin is",
"     <b>",
"      not",
"     </b>",
"     indicated for use under the following conditions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cancer patients receiving hormonal therapy, therapeutic biologic products, or radiation therapy unless also receiving concurrent myelosuppressive chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cancer patients receiving myelosuppressive chemotherapy when the expected outcome is curative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgery patients who are willing to donate autologous blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgery patients undergoing cardiac or vascular surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; As a substitute for RBC transfusion in patients requiring immediate correction of anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     In clinical trials (and one meta-analysis), epoetin has not demonstrated improved quality of life, fatigue, or well-being.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F165804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptomatic anemia in myelodysplastic syndrome (MDS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F165818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epoetin alfa may be confused with darbepoetin alfa, epoetin beta",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epogen&reg; may be confused with Neupogen&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Epopen [Spain] may be confused with EpiPen brand name for epinephrine [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (3% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (10% to 42%), headache (5% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (12% to 21%), rash (2% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (35% to 56%), vomiting (12% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (10% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (4% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Deep vein thrombosis, edema, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills, depression, dizziness, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dysphagia, stomatitis, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Clotted vascular access",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain, muscle spasm, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism, respiratory congestion, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylactic reaction, angioedema, bronchospasm, erythema, hypersensitivity reactions, hypertensive encephalopathy, microvascular thrombosis, MI, neutralizing antibodies, porphyria, pure red cell aplasia (PRCA), renal vein thrombosis, retinal artery thrombosis, seizure, stroke, tachycardia, temporal vein thrombosis, thrombophlebitis, TIA, tumor progression",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to epoetin or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (due to epoetin or other epoetin protein drugs); multidose vials contain benzyl alcohol and are contraindicated in neonates, infants, pregnant women, and nursing women",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Potentially serious allergic reactions have been reported (rarely), including rash and urticaria. Discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, thromboembolic events, stroke,  and mortality in clinical studies when administered to target hemoglobin levels &gt;11 g/dL",
"     </b>",
"     (and provide no additional benefit);  a rapid rise in hemoglobin (&gt;1 g/dL over 2 weeks) may also contribute to these risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pure red cell aplasia (PRCA): Cases of severe anemia and PRCA have been reported, predominantly in patients with chronic kidney disease receiving SubQ epoetin (the I.V. route is preferred for hemodialysis patients); cases have also been reported in patients with hepatitis C who were receiving ESAs, interferon, and ribavirin. Patients with a sudden loss of response (with severe anemia and a low reticulocyte count) should be evaluated for PRCA with associated neutralizing antibodies to erythropoietin; discontinue treatment (permanently) in patients with PRCA secondary to neutralizing antibodies to erythropoietin. Antibodies may cross-react; do not switch to another ESA in patients who develop antibody-mediated anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cancer patients:",
"     <b>",
"      [U.S. Boxed Warning]: A shortened overall survival and/or increased risk of tumor progression or recurrence has been reported in studies with breast, cervical, head and neck, lymphoid, and nonsmall cell lung cancer patients.",
"     </b>",
"     It is of note that in these studies, patients received ESAs to a target hemoglobin of &ge;12 g/dL; although risk has not been excluded when dosed to achieve a target hemoglobin of &lt;12 g/dL.",
"     <b>",
"      [U.S. Boxed Warnings]: To decrease these risks, and risk of cardio and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs in cancer patients only for the treatment of anemia related to concurrent myelosuppressive chemotherapy; discontinue ESA following completion of the chemotherapy course. ESAs are",
"      <span style=\"text-decoration: underline\">",
"       not",
"      </span>",
"      indicated for patients receiving myelosuppressive therapy when the anticipated outcome is curative.",
"     </b>",
"     A dosage modification is appropriate if hemoglobin levels rise &gt;1 g/dL per 2-week time period during treatment (Rizzo, 2010). Use of ESAs has been associated with an increased risk of venous thromboembolism (VTE) without a reduction in transfusions in patients &gt;65 years of age with cancer (Hershman, 2009). Improved anemia symptoms, quality of life, fatigue, or well-being have not been demonstrated in controlled clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic kidney disease patients:",
"     <b>",
"      [U.S. Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke was reported in chronic kidney disease (CKD) patients administered ESAs to target hemoglobin levels &ge;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions. An optimal target hemoglobin level, dose or dosing strategy to reduce these risks has not been identified in clinical trials.",
"     </b>",
"     Hemoglobin rising &gt;1 g/dL in a 2-week period may contribute to the risk (dosage reduction recommended). CKD patients who exhibit an inadequate hemoglobin response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. ESA therapy may reduce dialysis efficacy (due to increase in red blood cells and decrease in plasma volume); adjustments in dialysis parameters may be needed. Patients treated with epoetin may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension/cardiovascular disease: Use with caution in patients with a history of hypertension (contraindicated in uncontrolled hypertension). An excessive rate of rise of hemoglobin is associated with hypertension or exacerbation of hypertension; decrease the epoetin dose if the hemoglobin increase exceeds 1 g/dL in any 2-week period. Blood pressure should be controlled prior to start of therapy and monitored closely throughout treatment. Hypertensive encephalopathy has been reported with patients receiving erythropoietic therapy; monitor closely and control blood pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Perisurgery patients:",
"     <b>",
"      [U.S. Boxed Warning]: DVT prophylaxis is recommended in perisurgery patients due to the increased risk of DVT.",
"     </b>",
"     Increased mortality was also observed in patients undergoing coronary artery bypass surgery who received epoetin alfa; these deaths were associated with thrombotic events. Epoetin is",
"     <b>",
"      not",
"     </b>",
"     approved for reduction of red blood cell transfusion in patients undergoing cardiac or vascular surgery and is",
"     <b>",
"      not",
"     </b>",
"     indicated for surgical patients willing to donate autologous blood.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: The risk for seizures is increased with epoetin use in patients with chronic kidney disease; use with caution in patients with a history of seizures. Monitor closely for neurologic symptoms during the first several months of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Severe anemia or acute blood loss: Due to the delayed onset of erythropoiesis, epoetin is not recommended for acute correction of severe anemia or as a substitute for emergency transfusion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage form specific issues:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Product may contain albumin, which confers a theoretical risk of transmission of viral disease or Creutzfeldt-Jakob disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Multidose vials contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Factors impairing erythropoiesis: Prior to treatment, correct or exclude deficiencies of iron, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     , and/or folate, as well as other factors which may impair erythropoiesis (inflammatory conditions, infections, bleeding). Poor response to therapy should prompt evaluation of potential factors impairing erythropoiesis, as well as possible malignant processes and hematologic disease (thalassemia, refractory anemia, myelodysplastic disorder), occult blood loss, hemolysis, ostetis fibrosa cystic, and/or bone marrow fibrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iron supplementation: Prior to and periodically during therapy, iron stores must be evaluated. Supplemental iron is recommended if serum ferritin &lt;100 mcg/L or serum transferrin saturation &lt;20%. Most patients with chronic kidney disease will require iron supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Because of the risks of decreased survival and increased risk of tumor growth or progression, all healthcare providers and hospitals are required to enroll and comply with the ESA APPRISE Oncology Program prior to prescribing or dispensing ESAs to cancer patients.",
"     </b>",
"     Prescribers and patients will have to provide written documentation of discussed risks prior to each new epoetin course.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. In vitro studies suggest that recombinant erythropoietin does not cross the human placenta (Reisenberger, 1997). Polyhydramnios and intrauterine growth retardation have been reported with use in women with chronic kidney disease (adverse effects also associated with maternal disease). Hypospadias and pectus excavatum have been reported with first trimester exposure (case report).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Recombinant erythropoietin alfa has been evaluated as adjunctive treatment for severe pregnancy associated iron deficiency anemia (Breymann, 2001; Krafft, 2009) and has been used in pregnant women with iron-deficiency anemia associated with chronic kidney disease (CKD) (Furaz-Czerpak 2012; Josephson, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Amenorrheic premenopausal women should be cautioned that menstruation may resume following treatment with recombinant erythropoietin (Furaz-Czerpak, 2012). Multidose formulations containing benzyl alcohol are contraindicated for use in pregnant women; if treatment during pregnancy is needed, single dose preparations should be used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Women who become pregnant during treatment with epoetin are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (1-800-772-6436).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F165750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous erythropoietin is found in breast milk (Semba, 2002). It is not known if recombinant erythropoietin alfa is excreted into breast milk. The manufacturer recommends caution be used if the single dose vial preparation is administered to nursing women; use of the multiple dose vials containing benzyl alcohol is contraindicated in breast-feeding women. When administered enterally to neonates (mixed with human milk or infant formula), recombinant erythropoietin did not significantly increase serum EPO concentrations. If passage via breast milk does occur, risk to a nursing infant appears low (Juul, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F165748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Epogen Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2000 units/mL (1 mL): $31.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3000 units/mL (1 mL): $47.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4000 units/mL (1 mL): $63.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 units/mL (1 mL): $157.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000 units/mL (1 mL): $315.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Procrit Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2000 units/mL (1 mL): $44.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3000 units/mL (1 mL): $66.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4000 units/mL (1 mL): $88.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 units/mL (1 mL): $221.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20000 units/mL (1 mL): $442.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40000 units/mL (1 mL): $884.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F165736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Transferrin saturation and serum ferritin (prior to and during treatment); hemoglobin (weekly after initiation and following dose adjustments until stable and sufficient to minimize need for RBC transfusion, CKD patients should be also be monitored at least monthly following hemoglobin stability); blood pressure; seizures (CKD patients following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:2em;text-align:justify;\">",
"     Cancer patients: Examinations recommended by the ASCO/ASH guidelines (Rizzo, 2010) prior  to treatment include: peripheral blood smear (in some situations a bone marrow exam may be necessary), assessment for iron, folate, or vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency, reticulocyte count, renal function status, and occult blood loss; during ESA treatment, assess baseline and periodic iron, total iron-binding capacity, and transferrin saturation or ferritin levels.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F165739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Zidovudine-treated HIV patients: Available evidence indicates patients with endogenous serum erythropoietin levels &gt;500 mU/mL are unlikely to respond",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F165751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Binocrit (GB, MY);",
"     </li>",
"     <li>",
"      Efotin (PH);",
"     </li>",
"     <li>",
"      EPIAO (TH);",
"     </li>",
"     <li>",
"      Epogen (PH);",
"     </li>",
"     <li>",
"      Epokine (PH);",
"     </li>",
"     <li>",
"      Eporon (TH);",
"     </li>",
"     <li>",
"      Eposino (PH);",
"     </li>",
"     <li>",
"      Eposis (KP, TH);",
"     </li>",
"     <li>",
"      Epovax (PH);",
"     </li>",
"     <li>",
"      Eprex (AE, AR, AU, BB, BD, BE, BG, BH, BM, BS, BZ, CH, CL, CR, CY, CZ, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, IL, IN, IQ, IR, IT, JM, JO, KW, LB, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PY, QA, RU, SA, SE, SG, SR, SV, SY, TH, TR, TT, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Eritrogen (TH);",
"     </li>",
"     <li>",
"      Erypo (AT, DE);",
"     </li>",
"     <li>",
"      Espo (CL, JP);",
"     </li>",
"     <li>",
"      Espogen (TH);",
"     </li>",
"     <li>",
"      Hemapo (ID);",
"     </li>",
"     <li>",
"      Hemax (TH);",
"     </li>",
"     <li>",
"      Hypercrit (BR, CN);",
"     </li>",
"     <li>",
"      Neorecormon (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Renogen (PH, TH);",
"     </li>",
"     <li>",
"      Yi Pu Li (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose response relationship with this effect. This results in an increase in reticulocyte counts followed by a rise in hematocrit and hemoglobin levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Several days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Hemoglobin level: 2-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 9 L; rapid in the plasma compartment; concentrated in liver, kidneys, and bone marrow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Some degradation does occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: ~21% to 31%; intraperitoneal epoetin: 3% (Macdougall, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Cancer: SubQ: 16-67 hours; Chronic kidney disease: I.V.: 4-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Chronic kidney disease: SubQ: 5-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (majority); urine (small amounts, 10% unchanged in normal volunteers)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bennett CL, Cournoyer D, Carson KR, et al, \"Long-Term Outcome of Individuals With Pure Red Cell Aplasia and Antierythropoietin Antibodies in Patients Treated With Recombinant Epoetin: A Follow-up Report From the Research on Adverse Drug Events and Reports (RADAR) Project,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2005, 106(10):3343-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/16099877/pubmed\" id=\"16099877\" target=\"_blank\">",
"        16099877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bennett CL, Silver SM, Djulbegovic B, et al, &ldquo;Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2008, 299(8):914-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/18314434/pubmed\" id=\"18314434\" target=\"_blank\">",
"        18314434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Breymann C, Visca E, Huch R, et al, \"Efficacy and Safety of Intravenously Administered Iron Sucrose With and Without Adjuvant Recombinant Human Erythropoietin for the Treatment of Resistant Iron-Deficiency Anemia During Pregnancy,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2001, 184(4):662-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/11262469/pubmed\" id=\"11262469\" target=\"_blank\">",
"        11262469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corbo DC, Suddith RL, Sharma B, et al, &ldquo;Stability, Potency, and Preservative Effectiveness of Epoetin Alfa After Addition of a Bacteriostatic Diluent,&rdquo;",
"      <i>",
"       Am J Hosp Pharm",
"      </i>",
"      , 1992, 49(6):1455-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/1529989/pubmed\" id=\"1529989\" target=\"_blank\">",
"        1529989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corwin HL, Gettinger A, Fabian TC, et al, \"Efficacy and Safety of Epoetin Alfa in Critically Ill Patients,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(10):965-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/17804841/pubmed\" id=\"17804841\" target=\"_blank\">",
"        17804841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corwin HL, Gettinger A, Pearl RG, et al, &ldquo;Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(22):2827-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/12472324/pubmed\" id=\"12472324\" target=\"_blank\">",
"        12472324",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cournoyer D, Toffelmire EB, Wells GA, et al, \"Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia After Treatment With Recombinant Erythropoietin Products: Recommendations for Minimization of Risk,\"",
"      <i>",
"       J Am Soc Nephrol",
"      </i>",
"      , 2004, 15(10):2728-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/15466278/pubmed\" id=\"15466278\" target=\"_blank\">",
"        15466278",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 2008, 34(1):17-60. Available at",
"      <a href=\"file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf\" target=\"_blank\">",
"       file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249616/pdf/134_2007_Article_934.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/18058085/pubmed\" id=\"18058085\" target=\"_blank\">",
"        18058085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drueke TB, Locatelli F, Clyne N, et al, &ldquo;Normalization of Hemoglobin Level in Patients With Chronic Kidney Disease and Anemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(20): 2071-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feusner J and Hastings C, &ldquo;Recombinant Human Erythropoietin in Pediatric Oncology: A Review,&rdquo;",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 2002, 39(4):463-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/12203665/pubmed\" id=\"12203665\" target=\"_blank\">",
"        12203665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furaz-Czerpak KR, Fern&aacute;ndez-Ju&aacute;rez G, Moreno-de la Higuera M&Aacute;, et al, \"Pregnancy in Women on Chronic Dialysis: A Review,\"",
"      <i>",
"       Nefrologia",
"      </i>",
"      , 2012, 32(3):287-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/22508145/pubmed\" id=\"22508145\" target=\"_blank\">",
"        22508145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hebert PC, Wells G, Blajchman MA, et al, &ldquo;A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(6):409-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/9971864/pubmed\" id=\"9971864\" target=\"_blank\">",
"        9971864",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershman DL, Buono DL, Malin J, et al, &ldquo;Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2009, 101(23):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/19903808/pubmed\" id=\"19903808\" target=\"_blank\">",
"        19903808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joosten E, Van Hove L, Lesaffre E, et al, &ldquo;Serum Erythropoietin Levels in Elderly Inpatients With Anemia of Chronic Disorders and Iron Deficiency Anemia,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1993, 41(12):1301-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/8227911/pubmed\" id=\"8227911\" target=\"_blank\">",
"        8227911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Josephson MA and McKay DB, \"Considerations in the Medical Management of Pregnancy in Transplant Recipients,",
"      <i>",
"       Adv Chronic Kidney Dis",
"      </i>",
"      , 2007, 14(2):156-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/17395118/pubmed\" id=\"17395118\" target=\"_blank\">",
"        17395118",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul SE and Christensen RD, &ldquo;Absorption of Enteral Recombinant Human Erythropoietin By Neonates,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2003, 37(6):782-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/12773061/pubmed\" id=\"12773061\" target=\"_blank\">",
"        12773061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP, et al, \"Incidence of Recombinant Erythropoietin (EPO) Hyporesponse, EPO-Associated Antibodies, and Pure Red Cell Aplasia in Dialysis Patients,\"",
"      <i>",
"       Kidney Int",
"      </i>",
"      , 2005, 68(3):1215-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/16105053/pubmed\" id=\"16105053\" target=\"_blank\">",
"        16105053",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krafft A, Bencaiova G, and Breymann C, \"Selective Use of Recombinant Human Erythropoietin in Pregnant Patients With Severe Anemia or Nonresponsive to Iron Sucrose Alone,\"",
"      <i>",
"       Fetal Diagn Ther",
"      </i>",
"      ,  2009, 25(2):239-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/19506383/pubmed\" id=\"19506383\" target=\"_blank\">",
"        19506383",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Macdougall IC, Roberts DE, Neubert P, et al, &ldquo;Pharmacokinetics of Recombinant Human Erythropoietin in Patients on Continuous Ambulatory Peritoneal Dialysis,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1989, 1(8635):425-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/2563798 /pubmed\" id=\"2563798 \" target=\"_blank\">",
"        2563798",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nafziger J, Pailla K, Luciani L, et al, &ldquo;Decreased Erythropoietin Responsiveness to Iron Deficiency Anemia in the Elderly,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 1993, 43(3):172-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/8352231/pubmed\" id=\"8352231\" target=\"_blank\">",
"        8352231",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Napolitano LM, Fabian TC, Kelly KM, et al, \"Improved Survival of Critically Ill Trauma Patients Treated With Recombinant Human Erythropoietin,\"",
"      <i>",
"       J Trauma",
"      </i>",
"      , 2008, 65(2):285-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/18695463/pubmed\" id=\"18695463\" target=\"_blank\">",
"        18695463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Cancer- and Chemotherapy-Induced Anemia Version 1.2012.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Practice Guidelines in Oncology&trade;: Myelodysplastic Syndromes Version 2.2011.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/mds.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Kidney Foundation, &ldquo;KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2007, 50(3):529-30. Available at file://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm or  file://www.kidney.org/professionals/KDOQI",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naughton CA, Duppong LM, Forbes KD, et al, \"Stability of Multidose, Preserved Formulation Epoetin Alfa in Syringes for Three and Six Weeks,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2003, 60(5):464-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/12635452/pubmed\" id=\"12635452\" target=\"_blank\">",
"        12635452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phronmmintikul A, Haas SJ, Elsik M, et al, &ldquo;Mortality and Target Haemoglobin Concentrations in Anaemic Patients with Chronic Kidney Disease Treated With Erythropoietin: A Meta-Analysis,",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 369(9559):381-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/17276778/pubmed\" id=\"17276778\" target=\"_blank\">",
"        17276778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reisenberger K, Egarter C, Kapiotis S, et al, \"Transfer of Erythropoietin Across the Placenta Perfused",
"      <i>",
"       in vitro",
"      </i>",
"      ,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 1997, 89(5 Pt 1):738-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/9166312/pubmed\" id=\"9166312\" target=\"_blank\">",
"        9166312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizzo JD, Brouwers M, Hurley P, et al, &ldquo;American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(33):4996-5010.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/20975064/pubmed\" id=\"20975064\" target=\"_blank\">",
"        20975064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rizzo JD, Somerfield MR, Hagerty LK, et al, &ldquo;American Society of Hematology/American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2008, 111(1):25-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/17954703/pubmed\" id=\"17954703\" target=\"_blank\">",
"        17954703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Semba RD and Juul SE, \"Erythropoietin in Human Milk: Physiology and Role in Infant Health,\"",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2002,  18(3):252-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/12192960/pubmed\" id=\"12192960\" target=\"_blank\">",
"        12192960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh AJ, Szczech L, Tang Kl, et al, &ldquo;Correction of Anemia With Epoetin Alfa in Chronic Kidney Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(20):2085-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/17108343/pubmed\" id=\"17108343\" target=\"_blank\">",
"        17108343",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Society of Thoracic Surgeons Blood Conservation Guideline Task Force and Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, &ldquo;Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2007, 83(5 Suppl):27-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/17462454/pubmed\" id=\"17462454\" target=\"_blank\">",
"        17462454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teehan G and Benz RL, &ldquo;An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost,&rdquo;",
"      <i>",
"       Anemia",
"      </i>",
"      , 2011, 2011:623673.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/48/2825/abstract-text/21541213/pubmed\" id=\"21541213\" target=\"_blank\">",
"        21541213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinthal JA, &ldquo;The Role of Cytokines Following Bone Marrow Transplantation: Indications and Controversies,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 1996, 18(Suppl 3):10-4.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9410 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2825=[""].join("\n");
var outline_f2_48_2825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708743\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165764\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165765\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165808\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165767\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165789\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165768\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822431\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822432\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165738\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533184\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165724\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233735\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874643\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165742\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165816\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165741\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165804\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165818\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165806\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165745\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165728\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299274\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220130\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165734\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165749\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165775\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165750\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165748\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165736\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165739\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165751\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165727\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165744\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9410\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9410|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/12/25797?source=related_link\">",
"      Epoetin alfa: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/51/17208?source=related_link\">",
"      Epoetin alfa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_48_2826="Management of obstructive sleep apnea in adults";
var content_f2_48_2826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/48/2826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/48/2826/contributors\">",
"     Meir H Kryger, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/48/2826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/48/2826/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/48/2826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/48/2826/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/48/2826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a disorder that is characterized by obstructive apneas and hypopneas due to repetitive collapse of the upper airway during sleep. It has many potential consequences, including excessive daytime sleepiness, impaired daytime function, metabolic dysfunction, and an increased risk of cardiovascular disease and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of obstructive sleep apnea is reviewed here. The prevalence, risk factors, natural history, clinical manifestations, and diagnosis of OSA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link\">",
"     \"Overview of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of a patient with OSA begins by firmly establishing the diagnosis and its severity. Disease severity guides management by identifying patients who are at greatest risk for adverse outcomes and by providing a baseline from which to measure the effectiveness of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"     1",
"    </a>",
"    ]. Diagnosis and disease severity are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Disease spectrum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis of OSA is confirmed and its severity determined, the results of all testing should be reviewed with the patient. The patient should be educated about the risk factors, natural history, and consequences of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the patient should be warned about the potential consequences of driving or operating other dangerous equipment while sleepy and counseled to avoid activities that require vigilance and alertness if sleepy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=see_link\">",
"     \"Performance and safety risks of sleep deprivation and sleep disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8294?source=see_link\">",
"     \"Liabilities of sleep deprivation and sleep disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Finally, it should be determined whether treatment is indicated and, if so, which therapy is most appropriate. The potential benefits of successfully treating OSA include clinical improvement (eg, less daytime sleepiness, better quality of life, improved hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], reduced health care utilization and costs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/6,7\">",
"     6,7",
"    </a>",
"    ], and, possibly, decreased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavior modification is indicated for all patients who have OSA and a modifiable risk factor. Whether OSA-specific therapy (positive airway pressure, an oral appliance, upper airway surgery) is also indicated depends upon the frequency and severity of both respiratory events (eg, apneas, hypopneas) and oxyhemoglobin desaturation episodes during sleep, as well as the severity of any clinical sequelae. When indicated, OSA-specific therapy should be initiated concomitantly with behavior modification, rather than being delayed until the success or failure of behavior modification has been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different organizations advocate different thresholds for the initiation of treatment, as the following examples demonstrate:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American Academy of Sleep Medicine (AASM) recommends offering positive airway pressure therapy to all patients who have OSA on the basis of expert consensus [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1,9\">",
"       1,9",
"      </a>",
"      ]. They define OSA as either an obstructive respiratory disturbance index (RDI) greater than 15 events per hour, or an obstructive RDI between 5 and 14 events per hour that is accompanied by daytime sleepiness, loud snoring, witnessed breathing interruptions, or awakenings due to gasping or choking. The obstructive RDI is the number of obstructive apneas, obstructive hypopneas, and respiratory effort related arousals per hour of sleep. Alternative therapies (eg, an oral appliance or upper airway surgery) may be offered to patients who decline positive airway pressure therapy and who have mild to moderate OSA, amenable upper airway anatomy, and a preference for such treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H13#H13\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory disturbance index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Centers for Medicare and Medicaid Services (CMS) in the United States has its own guidelines for reimbursement of positive airway pressure therapy. Positive airway pressure therapy for OSA is reimbursed when the apnea hypopnea index (AHI) is greater than 15 events per hour, or between 5 and 14 events per hour and associated with excessive daytime sleepiness, impaired neurocognitive function, mood disorders, insomnia, cardiovascular disease (eg, hypertension, ischemic heart disease), or a history of stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/10\">",
"       10",
"      </a>",
"      ]. The AHI is the number of apneas and hypopneas per hour of sleep. CMS will also reimburse for positive airway therapy if the OSA was diagnosed on the basis of an abnormal RDI. This permits therapy to be instituted on the basis of home testing. However, it is important to realize that the CMS defines the RDI as the number of apneas and hypopneas per hour of recording. This is different than the usual definition of the RDI because it does not count respiratory effort related arousals and it is calculated per hour of recording rather than per hour of sleep. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H13#H13\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory disturbance index'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our practice is slightly different, as shown in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef70443 \" href=\"UTD.htm?25/58/26541\">",
"     algorithm 1",
"    </a>",
"    ). We consider the AHI (or RDI) and whether the patient has clinical or physiological symptoms or sequelae attributable to OSA when determining whether to initiate OSA-specific treatment. The symptoms or sequelae that we consider include a history of choking, gasping, witnessed apnea, subjective excessive daytime sleepiness (eg, drowsy driving or motor vehicle crash due to falling asleep), objective excessive daytime sleepiness (eg, confirmed by an abnormal multiple sleep latency test, maintenance of wakefulness test, or other validated measure of performance or vigilance), impaired neurocognitive function, mood disorders, insomnia, and hypoxemia (ie, repetitive drops in SpO2 to &lt;85 percent during the respiratory events). The AHI and RDI are defined elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H12#H12\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea hypopnea index'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H13#H13\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory disturbance index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We favor the initiation of OSA-specific therapy in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has one or more clinical or physiological sequelae attributable to sleep apnea and an AHI (or RDI) that is &gt;5 events per hour of sleep.",
"     </li>",
"     <li>",
"      The patient performs mission critical work (eg, airline pilot, bus and truck drivers) and has an AHI (or RDI) that is &gt;5 events per hour of sleep, even if there are no clinical or physiological sequelae attributable to sleep apnea. There are no empirical studies that address this indication; therefore, it is based upon clinical experience and rationale.",
"     </li>",
"     <li>",
"      The patient has an abnormal frequency of respiratory effort related arousals (eg, &ge;10 RERAs) and either subjective or objective excessive daytime sleepiness, even if the AHI is &le;5 events per hour [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H8#H8\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory effort related arousals'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to notice that cardiovascular diseases (eg, systemic hypertension, ischemic heart disease, arrhythmias) are not among the clinical and physiological sequelae attributable to OSA that are listed above. Whether cardiovascular disease alone warrants OSA-specific therapy among patients with an abnormal AHI or RDI is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The urgency with which we initiate therapy is influenced in large part by the frequency, depth, and duration of oxyhemoglobin desaturation. As an example, urgency is indicated if greater than five minutes is spent with the SpO2 continuously below 88 percent.",
"   </p>",
"   <p>",
"    The benefit of using an AHI greater than five events per hour (instead of a higher value) as the threshold for therapy in symptomatic patients was illustrated by a trial that randomly assigned 16 patients with an AHI of 5 to 15 events per hour to receive continuous positive airway pressure (CPAP) or a sham therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/12\">",
"     12",
"    </a>",
"    ]. CPAP improved symptoms and daytime function.",
"   </p>",
"   <p>",
"    The benefit of therapy for patients with an increased frequency of RERAs and daytime sleepiness, but an AHI of five events per hour or less, was illustrated by a trial that used a respiratory disturbance index (RDI, the number of apneas, hypopneas, and RERAs per hour of sleep) greater than five events per hour as the threshold for initiating positive airway pressure therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared to trials that used higher thresholds, the magnitude of benefit was similar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H13#H13\">",
"     \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory disturbance index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Choosing a therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The types of behavior modification that should be instituted depend upon the characteristics of the patient. Overweight or obese patients should be encouraged to lose weight. Patients with positional OSA should change their sleep position accordingly. All patients should abstain from alcohol and avoid medications that may worsen their OSA. These interventions are described in detail below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Behavior modification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The choice of an airway-specific therapy (positive airway pressure, an oral appliance, upper airway surgery) depends upon the severity of the OSA, patient preference, and upper airway anatomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with severe OSA (AHI &gt;30 events per hour",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe clinical sequelae), severe hypoxemia (ie, the SpO2 repeatedly goes below 80 percent), or sustained hypoxemia (ie, &ge;5 minutes with an SpO2 below 88 percent), we use positive airway pressure as first-line therapy. This is based upon the variable efficacy of oral appliances in this patient population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link&amp;anchor=H14#H14\">",
"       \"Oral appliances in the treatment of obstructive sleep apnea in adults\", section on 'Outcome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with mild or moderate OSA (AHI &le;30 events per hour without severe clinical sequelae) who do not express a preference, we prefer positive airway pressure rather than an oral appliance because the former is superior at reducing the frequency of obstructive events. However, we will initiate an oral appliance rather than positive airway pressure if the patient prefers an oral appliance. This is based upon our recognition that most patients prefer an oral appliance, adherence is an essential aspect of successful treatment, both modalities are effective compared to no treatment or a sham treatment, and both modalities have a similar effect on symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link&amp;anchor=H14#H14\">",
"       \"Oral appliances in the treatment of obstructive sleep apnea in adults\", section on 'Outcome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We consider surgical therapy when positive airway pressure or an oral appliance is declined, ineffective (after at least a three month trial of therapy), or not an option. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While the above approach encompasses most patients with OSA, there are a few uncommon scenarios in which we deviate from this strategy. For patients with severe, life-threatening apnea that cannot be controlled by other means, tracheotomy may be the only treatment option. We consider apnea to be life-threatening if there are apnea-related bradyarrhythmias such as asystole, apnea-related tachyarrhythmias such as atrial",
"    <span class=\"nowrap\">",
"     fibrillation/flutter",
"    </span>",
"    or ventricular tachycardia, or the SpO2 repeatedly falls below 75 percent. For patients whose OSA is due to a surgically correctable obstructing lesion, surgical resection of the obstructing lesion is first-line therapy. Examples of surgically correctable lesions that may obstruct the upper airway include tonsillar hypertrophy, adenoid hypertrophy, or craniofacial abnormalities.",
"   </p>",
"   <p>",
"    Whenever positive airway pressure is the therapy chosen, available modes include continuous positive airway pressure (CPAP), bilevel positive airway pressure (BPAP), and autotitrating positive airway pressure (APAP). We generally favor CPAP because it is the most familiar and best studied. A trial of BPAP or APAP is appropriate for patients who do not tolerate CPAP. BPAP is appropriate initial therapy for patients with coexisting central sleep apnea or significant hypoventilation. Selection of the mode of positive airway pressure is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10296?source=see_link\">",
"     \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BEHAVIOR MODIFICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss should be recommended to all patients who are overweight or obese [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. This is based on evidence that weight loss improves overall health, decreases the apnea hypopnea index (AHI, the number of apneas and hypopneas per hour of sleep), improves quality of life, and probably decreases daytime sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of weight loss on OSA were illustrated by a trial that enrolled 72 consecutive overweight patients (mean BMI 32",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    with mild OSA (mean AHI 10 events per hour of sleep) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/17\">",
"     17",
"    </a>",
"    ]. The patients were randomly assigned to receive a single session of general nutrition and exercise advice, or a more intensive program that included a low calorie diet for three months plus nutrition and exercise counseling for one year. Patients in the latter group had significantly greater weight loss, reduction in the AHI, and improvement in quality of life compared to the control group. There was no difference in the degree of improvement in daytime sleepiness, but the relevance of this is uncertain since the degree of daytime sleepiness was barely abnormal at baseline. Smaller studies that included patients with more severe OSA and more daytime sleepiness at baseline suggest that weight loss also improves daytime sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of weight loss achieved via bariatric surgery on OSA appears to be similar. This was shown in a trial that randomized 60 obese patients (mean BMI 43 to 46",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    with moderate to severe OSA (mean AHI 57 to 65 events per hour of sleep) to a conventional weight loss program that included regular consultations with a dietitian and physician for two years and the use of very low-calorie diets as necessary, or laparoscopic adjustable gastric banding [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients in both groups had a significant reduction in the AHI (from 57 to 43 events per hour in the conventional group and 65 to 40 events per hour in the surgical group), improvement in daytime sleepiness, and reduction in symptoms of depression between baseline and two years. There was no significant difference in the degree of improvement between groups, despite significantly greater weight loss in the surgery group (27.8 kg vs 5.1 kg at two years). Only one patient in the conventional group and none in the surgical group achieved OSA remission (defined as an AHI of less than five",
"    <span class=\"nowrap\">",
"     events/hour).",
"    </span>",
"    Meta-analyses of earlier observational studies have reported conflicting results on the benefits of bariatric surgery on OSA, in part because of varying selection criteria and lack of formal polysomnography outcome data in many of the studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link\">",
"     \"Surgical management of severe obesity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients whose OSA improves or resolves after weight loss should strive to maintain their weight loss, since weight gain is associated with worsening of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Such patients should also be followed closely because OSA may recur even in patients who maintain their weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Counseling regarding ongoing diet modification and exercise, as well as referral to a nutritionist may be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10842335\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise may modestly improve OSA even in the absence of significant weight loss.",
"   </p>",
"   <p>",
"    This was suggested by a trial that randomly assigned 43 patients with OSA to undergo exercise training (intervention) or a stretching program (control) for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/26\">",
"     26",
"    </a>",
"    ]. The exercise program consisted of 150 minutes per week of moderate intensity aerobic exercise performed four days per week. The aerobic exercise was followed by resistance training two days per week. Patients in the exercise training group had a significant reduction in their AHI measured by in-laboratory polysomnography (from 32.2 to 24.6 events per hour of sleep), despite there being no significant change in body weight. In contrast, patients in the stretching group did not have any improvement in their AHI (from 24.4 to 28.9 events per hour of sleep). Sixty-three percent of the exercise training group had a reduction in AHI of at least 20 percent.",
"   </p>",
"   <p>",
"    This trial had several important limitations. First, patient-important outcomes were not measured. Second, the applicability of the results to a typical clinical practice is uncertain because the patients were closely supervised during exercise and the study excluded patients with common morbidities, including cardiovascular disease, pulmonary disease, metabolic disease, uncontrolled hypertension, pregnancy, and the inability to exercise due to orthopedic or musculoskeletal problems. Finally, the short duration of the trial makes it impossible to know whether the benefits are sustained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sleep position",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the diagnostic sleep study, some patients will be observed to have OSA that develops or worsens during sleep in the supine position. These patients tend to have less severe OSA, to be less obese, and to be younger [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/27\">",
"     27",
"    </a>",
"    ]. Sleeping in a non-supine position (eg, lateral recumbent) may correct or improve OSA in such patients and should be encouraged. However, sleeping in a non-supine position should not be used as the primary therapy unless normalization of the AHI when sleeping in a non-supine position has been confirmed by polysomnography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1,27\">",
"     1,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of sleeping in a non-supine position was demonstrated by a crossover trial in which 13 patients with positional OSA (mean AHI 17 events per hour) were randomly assigned to sleep in a non-supine position or to receive continuous positive airway pressure (CPAP) for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/28\">",
"     28",
"    </a>",
"    ]. Both interventions significantly improved the AHI and oxyhemoglobin saturation compared to baseline, although CPAP was more effective in improving each of these parameters. There were no differences in the degree of improvement of clinical outcomes, such as daytime sleepiness.",
"   </p>",
"   <p>",
"    Approximately one-half of patients who are encouraged to sleep in the lateral position will learn to do so and will maintain the behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/29\">",
"     29",
"    </a>",
"    ]. A number of devices have been developed to reduce the likelihood of sleeping in the supine position, including posture alarms, special pillows, and modified nightshirts. A simple device that can be made at home is a snug-fitting T-shirt with a pocket sewn over the spine and tennis balls placed in the pocket. Obese patients may benefit from a harder type of ball, such as a baseball. The discomfort associated with rolling into the supine position is generally enough to prompt the patient to roll back into the lateral position without awakening. This technique appears to be limited by poor adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients, sleeping in a semi-recumbent position (ie, elevated head-of-the-bed or a reclining chair) may also be helpful. However, this position has not been as well studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Alcohol avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with OSA should avoid alcohol, even during the daytime, because it can depress the central nervous system, exacerbate OSA, worsen sleepiness, and promote weight gain. The effect of alcohol consumption was illustrated by a series with seven patients who had varying degrees of upper airway obstruction during sleep, ranging from snoring alone to OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/31\">",
"     31",
"    </a>",
"    ]. Following alcohol ingestion, the duration and frequency of obstructive respiratory events and the degree of oxyhemoglobin desaturation increased in five patients (71 percent). Two patients who had snoring alone at baseline developed frank OSA after alcohol ingestion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Medication selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any clinician who prescribes medication for the patient should be informed that the patient has OSA, since certain medications should be avoided if reasonable alternatives exist. These include medications that inhibit the central nervous system, such as benzodiazepines and benzodiazepine receptor agonists, as well as barbiturates, other anti-epileptic drugs, antidepressants, antihistamines, and opiates. Antidepressants that cause weight gain (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    ) might be particularly problematic in these patients. Some antidepressants may worsen sleep by causing restless legs syndrome or periodic limb movements. When such medications are felt to be necessary despite the patient's OSA, their use should be monitored closely and the dose carefully titrated if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17127?source=see_link\">",
"     \"The effects of medications on sleep quality and sleep architecture\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OSA-SPECIFIC THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;OSA-specific therapies include positive airway pressure, oral appliances, and upper airway surgery. For most patients in whom OSA-specific therapy is indicated, the appropriate initial therapy is either positive airway pressure or an oral appliance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Positive airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive airway pressure splints the upper airway open. As a result, respiratory events due to upper airway collapse (eg, apneas, hypopneas) are prevented.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive airway pressure therapy is generally considered first-line therapy for OSA. It can be delivered as continuous positive airway pressure (CPAP), bilevel positive airway pressure (BPAP), autotitrating positive airway pressure (APAP), adaptive servo-ventilation, or end expiratory positive airway pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CPAP delivers positive airway pressure at a level that remains constant throughout the respiratory cycle. It is used most often because it is the simplest, the most extensively studied, and associated with the most clinical experience. A pressure relief setting (ie, lowers the positive airway pressure at the onset of exhalation) is sometimes used to improve comfort and tolerance of the device.",
"     </li>",
"     <li>",
"      BPAP delivers a preset inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP). The tidal volume is related to the difference between the IPAP and EPAP. As an example, the tidal volume is greater using an IPAP of 15 cm H2O and an EPAP of 5 cm H2O (difference of 10 cm H2O), than an IPAP of 10 cm H2O and an EPAP of 5 cm H2O (difference of 5 cm H2O). There is no proven advantage to using BPAP instead of CPAP for the routine management of OSA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/33\">",
"       33",
"      </a>",
"      ]. BPAP should not be confused with BiPAP&reg;, which is the brand name of a single manufacturer and is just one of many devices that can deliver BPAP.",
"     </li>",
"     <li>",
"      APAP increases or decreases the level of positive airway pressure in response to a change in airflow, a change in circuit pressure, or a vibratory snore (signs that generally indicate that upper airway resistance has changed). The degree of improvement of major outcomes conferred by APAP and CPAP is similar [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. However, APAP is preferred by more patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/34\">",
"       34",
"      </a>",
"      ], although it has not been shown to improve adherence.",
"     </li>",
"     <li>",
"      Adaptive servo-ventilation provides a varying amount of inspiratory pressure superimposed on a low level of CPAP. It can be helpful in patients who develop central apneas when treated with CPAP (ie, complex sleep apnea), as well as in patients who require medications that can suppress respiration (eg, opiates), because it compensates for episodes of central apnea. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link&amp;anchor=H902709#H902709\">",
"       \"Central sleep apnea: Treatment\", section on 'Adaptive servo-ventilation (ASV)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      End-expiratory positive airway pressure (EPAP) is achieved with a disposable nasal device that allows for unimpeded inspiration, but provides increased resistance on expiration. Trials have documented efficacy of the EPAP device at 3 months and 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Selection of a mode, titration of the positive airway pressure level, and other aspects of initiating positive airway pressure therapy are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10296?source=see_link\">",
"     \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is high quality evidence from meta-analyses of randomized trials that positive airway pressure therapy reduces the frequency of respiratory events during sleep, decreases daytime sleepiness, and improves quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/2-4,38\">",
"     2-4,38",
"    </a>",
"    ]. This was best illustrated by a meta-analysis of 22 randomized trials (1160 patients) that compared nocturnal CPAP to a control [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/3\">",
"     3",
"    </a>",
"    ]. Controls included sham CPAP, placebo tablets, or conservative management, such as weight loss and sleep hygiene. Nocturnal CPAP significantly improved both subjective and objective sleepiness, quality of life, cognitive function, and depression. Mortality was not evaluated in this meta-analysis.",
"   </p>",
"   <p>",
"    There is also evidence that positive airway pressure therapy may improve the metabolic syndrome associated with OSA. This was demonstrated by a trial that randomly assigned 90 patients with OSA (mean AHI 48 events per hour of sleep) and excessive daytime sleepiness to receive either therapeutic CPAP or sham CPAP for three months, followed by a one month washout period and then crossover to the other intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/39\">",
"     39",
"    </a>",
"    ]. Compared with sham CPAP, therapeutic CPAP was associated with a reduction in daytime sleepiness and greater decreases in body mass index, subcutaneous fat, total cholesterol, non-high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and glycated hemoglobin. The interpretation of these results is complicated by the possibility that the improved lipid measurements were due to the reduction in adiposity. Since CPAP therapy has not been previously associated with weight loss, the reduced adiposity in the therapeutic CPAP group suggests that influences other than CPAP may have affected the outcomes; therefore, the results should be considered preliminary, but worthy of further study.",
"   </p>",
"   <p>",
"    No randomized trial has found that positive airway pressure therapy improves mortality in patients with OSA. This may be because early randomized trials that compared positive airway pressure to either no therapy or a sham therapy usually measured short-term outcomes, such as the frequency of respiratory events during sleep, daytime sleepiness, and quality of life. However, observational studies provide some insights into the effect of CPAP on mortality. An observational study of 1116 women referred for suspected OSA found that CPAP treatment caused a non-statistically significant decrease in cardiovascular mortality among women with severe OSA (adjusted hazard ratio 0.55, 95% CI 0.17-1.74) and mild to moderate OSA (adjusted hazard ratio 0.19, 95% CI 0.02-1.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/40\">",
"     40",
"    </a>",
"    ]. These findings indicate that there were too few deaths during the study to either confirm or exclude a mortality benefit. Important limitations of the study include that potential confounders (eg, differences in exercise between the groups, changes in blood pressure or lipid levels during the study) were not reported and measures that indicate whether the CPAP treatment was effective (ie, apnea hypopnea index, oxyhemoglobin saturation) were not reported. Other observational studies similarly suggest that CPAP may improve mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Favorable outcomes likely depend on adherence with positive airway pressure therapy. However, it is estimated that 20 to 40 percent of patients do not use their positive airway pressure device and many others do not use it all night, every night [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/43-49\">",
"     43-49",
"    </a>",
"    ]. Adherence with positive airway pressure therapy is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=see_link\">",
"     \"Adherence with continuous positive airway pressure (CPAP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oral appliances",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are an increasing number of oral appliances that are designed to either protrude the mandible forward (ie, mandibular",
"    <span class=\"nowrap\">",
"     advancement/repositioning",
"    </span>",
"    splints, devices, or appliances) or hold the tongue in a more anterior position (ie, tongue retaining devices). Either design holds the soft tissues of the oropharynx away from the posterior pharyngeal wall, thereby maintaining upper airway patency.",
"   </p>",
"   <p>",
"    Oral appliances decrease the frequency of respiratory events, arousals, and episodes of oxyhemoglobin desaturation, compared to no treatment or a sham intervention. They may also improve daytime sleepiness, quality of life, and neurocognitive function. Their impact on mortality is unknown. These outcomes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link&amp;anchor=H14#H14\">",
"     \"Oral appliances in the treatment of obstructive sleep apnea in adults\", section on 'Outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient assessment, device selection, device titration, follow-up, and adverse effects related to the use of oral appliances are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link\">",
"     \"Oral appliances in the treatment of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment appears to be most effective in patients who have OSA due to a severe, surgically correctable, obstructing lesion. As an example, surgery is a reasonable initial approach to treating a patient who has OSA that is likely due to tonsillar hypertrophy that is obstructing the pharyngeal airway [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1,14\">",
"     1,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus regarding the role of surgery in the absence of a strictly defined anatomic lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/50\">",
"     50",
"    </a>",
"    ]. Uvulopalatopharyngoplasty (UPPP) is one of the most common surgical procedures that is performed in this context. It involves resection of the uvula, redundant retrolingual soft tissue, and palatine tonsillar tissue. UPPP appears to achieve a surgical cure (defined as a postoperative AHI of &lt;5 events per hour of sleep) in only a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/51\">",
"     51",
"    </a>",
"    ], and may compromise subsequent CPAP therapy by promoting mouth leaking and reducing the maximal level of pressure tolerated by many patients treated with CPAP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/52\">",
"     52",
"    </a>",
"    ]. Moreover, improving or correcting the sleep-related breathing disorder is not guaranteed to improve the patient&rsquo;s symptoms, since symptoms can never be attributed to the OSA with absolute certainty.",
"   </p>",
"   <p>",
"    Laser-assisted and radiofrequency ablation (RFA) are less invasive variants of UPPP. Other common surgical procedures for OSA include septoplasty, rhinoplasty, nasal turbinate reduction, nasal polypectomy, palatal advancement pharyngoplasty, tonsillectomy, adenoidectomy, palatal implants (ie, Pillar procedure) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/53\">",
"     53",
"    </a>",
"    ], tongue reduction (partial glossectomy, lingual tonsillectomy), genioglossus advancement, and maxillomandibular advancement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/32\">",
"     32",
"    </a>",
"    ]. A systematic review reported that most of the evidence related to such surgical treatments is from case series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/54\">",
"     54",
"    </a>",
"    ]. Meta-analyses of data extracted from these series suggest that UPPP, laser-assisted uvulopalatoplasty, radiofrequency ablation, and maxillomandibular advancement (MMA) decrease the AHI. MMA is most consistently associated with a decreased AHI, although the morbidity of MMA has not been determined. These meta-analyses were limited by a serious risk for bias and inconsistency among the series.",
"   </p>",
"   <p>",
"    Only a small number of trials have directly compared surgery to either conservative management or a nonsurgical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/55\">",
"     55",
"    </a>",
"    ]. Overall, the trials have failed to consistently demonstrate a benefit from surgical therapy. While this could be a true effect, it may also reflect the small sample sizes, the heterogeneous patient populations, or the use of short-term outcome measures. Representative studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial randomly assigned 32 patients with OSA and &gt;50 percent obstruction at the palatal level to receive conservative management or to undergo UPPP, with or without mandibular osteotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/56\">",
"       56",
"      </a>",
"      ]. At one year, there was improvement of subjective daytime sleepiness in the UPPP group compared to conservative treatment group (as measured by a sleepiness scale that has not been validated) and more patients in the UPPP group had a normal oxygen desaturation index. However, the surgical complication rate was 22 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H14#H14\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Desaturation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In another trial, 90 patients with OSA (mean AHI approximately 20 events per hour) were randomly assigned to receive CPAP, RFA, or sham RFA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/57\">",
"       57",
"      </a>",
"      ]. Compared to sham RFA, RFA improved daytime sleepiness and quality of life despite the AHI remaining unchanged. Compared to CPAP, RFA had no effect on daytime sleepiness or quality of life, and the AHI improved a smaller amount. There was no increase in complications in the RFA group in this trial, but known complications of RFA include palatal mucosal breakdown, transient neuralgias, tongue base abscess formation, and airway compromise due to edema [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/58-61\">",
"       58-61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several long-term follow up studies performed 15 to 20 years after UPPP report patient satisfaction rates ranging from 50 to 75 percent but persistent side effects such as nasal regurgitation and swallowing problems in up to 38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/62-64\">",
"     62-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pharmacologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic agents have been investigated as primary therapeutic agents for the management of OSA, with the goal of replacing the more burdensome therapies described above. However, no pharmacologic agent has proven to be sufficiently effective to warrant replacement of such therapies. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3801?source=see_link\">",
"     \"Pharmacologic treatment of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Comparisons",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major OSA-specific therapies (positive airway pressure, oral appliances, surgery) have been directly compared:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct comparisons of positive airway pressure to oral appliances have used CPAP as the mode of positive airway pressure. Trials indicated that CPAP is more effective at reducing the frequency and severity of both respiratory events and oxyhemoglobin desaturation episodes during sleep, but not symptoms. Patients generally prefer oral appliances. The related trials are described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link&amp;anchor=H17#H17\">",
"       \"Oral appliances in the treatment of obstructive sleep apnea in adults\", section on 'Compared to positive airway pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct comparisons of oral appliances to surgery are scarce, but appear to favor oral appliances. This is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link&amp;anchor=H18#H18\">",
"       \"Oral appliances in the treatment of obstructive sleep apnea in adults\", section on 'Compared to surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct comparisons of surgery to positive airway pressure are also scarce. One trial randomly assigned 90 patients with OSA (mean AHI of about 20 events per hour) to receive temperature controlled radiofrequency tissue ablation (TCRFA), CPAP, or a sham intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/57\">",
"       57",
"      </a>",
"      ]. Patients who received CPAP had a significantly greater reduction in the AHI when compared to patients who received TCRFA. However, there was no difference in daytime subjective sleepiness or quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up for patients who receive OSA-specific therapy varies according to the chosen therapy. This section describes the appropriate follow-up for each type of OSA-specific therapy. The management of daytime sleepiness that persists despite adequate treatment of the OSA and the management of common comorbid conditions are also addressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Airway pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who elect to be treated with positive airway pressure should be evaluated frequently, especially during the first few weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"     1",
"    </a>",
"    ]. This may include frequent telephone calls and as-needed opportunities to meet face to face with a clinician. The purpose of frequent evaluations is to quickly identify and manage any side effects that develop, since this may affect long-term adherence with the therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=see_link\">",
"     \"Adherence with continuous positive airway pressure (CPAP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once any side effects of the positive airway pressure are successfully managed and the patient is adhering to the therapy, the patient should be asked whether the symptoms of OSA have resolved. An objective sleep evaluation is generally unnecessary if the symptoms of OSA have resolved, but repeat testing is indicated for patients who do not improve or who have recurrent or persistent symptoms such as daytime sleepiness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"     1",
"    </a>",
"    ]. Objective testing may consist of polysomnography or type 3 portable monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The purpose of such testing is to help the clinician determine the reason for the treatment failure. Possible causes of treatment failure include nonadherence, weight gain, an inappropriate level of prescribed positive pressure, or an additional disorder causing sleepiness (eg, narcolepsy) that may require alterations in the therapeutic regimen. A review of medications should also be undertaken since many drugs may lead to sleepiness. Sleep deprivation related to lifestyle may also negate the expected effects from treatment of apnea.",
"   </p>",
"   <p>",
"    Once the patient's positive airway pressure therapy has been optimized and symptoms resolved, a regimen of long-term follow-up should be established. Annual visits are reasonable, with more frequent visits in between if new issues arise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"     1",
"    </a>",
"    ]. The purpose of long-term follow-up is to assess usage and monitor for recurrent OSA, new side effects, an air leak, and fluctuations in body weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Oral devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with an oral appliance should be reevaluated soon after the initiation of treatment. Follow-up of patients being treated with an oral appliance is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link&amp;anchor=H13#H13\">",
"     \"Oral appliances in the treatment of obstructive sleep apnea in adults\", section on 'Follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo surgery for OSA should receive both surgical and medical follow-up. The frequency of surgical follow-up is determined by the type of surgery, but should include assessment of wound healing, the anatomical result, side effects, and complications. Once the surgical team determines that the swelling has resolved and healing is complete (usually one to three months after the procedure), the efficacy of the procedure should be assessed by asking whether the symptoms of OSA have resolved and by performing full polysomnography or type 3 portable monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reassessment is generally coordinated by the sleep specialist. Long-term follow-up by the sleep specialist is indicated to monitor for recurrent OSA. This approach is applicable to patients who underwent surgery because of an obstructing lesion or because an alternative therapy was declined, not an option, or ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Persistent sleepiness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy may be beneficial as adjunctive therapy for excessive daytime sleepiness that persists despite adequate conventional therapy (eg, positive airway pressure, oral appliances) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"     1",
"    </a>",
"    ]. Prior to the initiating pharmacologic therapy, adherence with conventional therapy should be confirmed and alternative causes of daytime sleepiness should be excluded. The use of pharmacologic therapy to treat persistent sleepiness is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3801?source=see_link\">",
"     \"Pharmacologic treatment of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;OSA has been associated with other medical conditions, such as hypertension, heart failure, and ischemic heart disease. Any comorbid condition that may be impacted by OSA should be monitored closely following the initiation of OSA-specific therapy. Therapy directed at such comorbidities may need to be modified once therapy for OSA is instituted. As an example, dosages of antihypertensive medications may need to be reduced after successful treatment of OSA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/48/2826/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=see_link\">",
"       \"Patient information: Daytime sleepiness (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=see_link\">",
"       \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive sleep apnea (OSA) is a disorder that is characterized by obstructive apneas and hypopneas due to repetitive collapse of the upper airway during sleep. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Behavior modification is indicated for most patients who have OSA. This includes losing weight (if overweight or obese), exercising, changing the sleep position (if OSA is positional), abstaining from alcohol, and avoiding certain medications. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Behavior modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Our approach to deciding when non-surgical OSA-specific therapy is indicated is illustrated in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef70443 \" href=\"UTD.htm?25/58/26541\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinical and physiological sequelae attributable to OSA include a history of choking, gasping, witnessed apnea, subjective excessive daytime sleepiness (eg, drowsy driving or motor vehicle crash due to falling asleep), objective excessive daytime sleepiness (eg, confirmed by an abnormal multiple sleep latency test, maintenance of wakefulness test, or other validated measure of performance or vigilance), impaired neurocognitive function, mood disorders, insomnia, and hypoxemia (ie, repetitive drops in SpO2 to &lt;85 percent during the respiratory events).",
"     </li>",
"     <li>",
"      For patients who have an AHI (or RDI) of &gt;5 events per hour of sleep AND clinical or physiological sequelae attributable to OSA that are so burdensome that therapy is desired, we recommend non-surgical OSA-specific treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who and have an AHI (or RDI) of &gt;5 events per hour AND perform \"mission critical work&rdquo;, we suggest non-surgical OSA-specific therapy even in the absence of clinical or physiological sequelae attributable to OSA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who have &ge;10 respiratory effort-related arousals (RERAs) per hour of sleep and either subjective or objective excessive daytime sleepiness, we suggest non-surgical OSA-specific therapy even if the AHI is &le;5 events per hour (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Whether cardiovascular disease alone warrants OSA-specific therapy among patients with an abnormal AHI or RDI is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=see_link&amp;anchor=H16#H16\">",
"       \"Cardiovascular effects of obstructive sleep apnea\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-surgical OSA-specific therapies include positive airway pressure and oral appliances. Recommendations describing whether to choose positive airway pressure or an oral appliance are provided separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=see_link&amp;anchor=H20#H20\">",
"       \"Oral appliances in the treatment of obstructive sleep apnea in adults\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical therapy is generally reserved for selected patients in whom positive airway pressure or an oral appliance was either declined, not an option, or ineffective. A notable exception is patients whose OSA is due to a surgically correctable obstructing lesion. For such patients, surgical resection of the obstructing lesion is first-line therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Choosing a therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who continue to have excessive daytime sleepiness despite adequate OSA-specific therapy that is severe enough to warrant treatment may benefit from pharmacologic therapy. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3801?source=see_link\">",
"       \"Pharmacologic treatment of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/1\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/2\">",
"      Sullivan CE, Issa FG, Berthon-Jones M, Eves L. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981; 1:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/3\">",
"      Giles TL, Lasserson TJ, Smith BJ, et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006; :CD001106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/4\">",
"      Patel SR, White DP, Malhotra A, et al. Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. Arch Intern Med 2003; 163:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/5\">",
"      Gay P, Weaver T, Loube D, et al. Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep 2006; 29:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/6\">",
"      Bahammam A, Delaive K, Ronald J, et al. Health care utilization in males with obstructive sleep apnea syndrome two years after diagnosis and treatment. Sleep 1999; 22:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/7\">",
"      Kapur V, Blough DK, Sandblom RE, et al. The medical cost of undiagnosed sleep apnea. Sleep 1999; 22:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/8\">",
"      He J, Kryger MH, Zorick FJ, et al. Mortality and apnea index in obstructive sleep apnea. Experience in 385 male patients. Chest 1988; 94:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/9\">",
"      Berry RB, Budhiraja R, Gottlieb DJ, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2012; 8:597.",
"     </a>",
"    </li>",
"    <li>",
"     www.cms.hhs.gov/Transmittals/Downloads/R35NCD.pdf (Accessed on July 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/11\">",
"      Downey R 3rd, Perkin RM, MacQuarrie J. Upper airway resistance syndrome: sick, symptomatic but underrecognized. Sleep 1993; 16:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/12\">",
"      Engleman HM, Martin SE, Deary IJ, Douglas NJ. Effect of CPAP therapy on daytime function in patients with mild sleep apnoea/hypopnoea syndrome. Thorax 1997; 52:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/13\">",
"      Redline S, Adams N, Strauss ME, et al. Improvement of mild sleep-disordered breathing with CPAP compared with conservative therapy. Am J Respir Crit Care Med 1998; 157:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/14\">",
"      Randerath WJ, Verbraecken J, Andreas S, et al. Non-CPAP therapies in obstructive sleep apnoea. Eur Respir J 2011; 37:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/15\">",
"      Browman CP, Sampson MG, Yolles SF, et al. Obstructive sleep apnea and body weight. Chest 1984; 85:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/16\">",
"      Smith PL, Gold AR, Meyers DA, et al. Weight loss in mildly to moderately obese patients with obstructive sleep apnea. Ann Intern Med 1985; 103:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/17\">",
"      Tuomilehto HP, Sepp&auml; JM, Partinen MM, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009; 179:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/18\">",
"      Dixon JB, Schachter LM, O'Brien PE, et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. JAMA 2012; 308:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/19\">",
"      Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/20\">",
"      Greenburg DL, Lettieri CJ, Eliasson AH. Effects of surgical weight loss on measures of obstructive sleep apnea: a meta-analysis. Am J Med 2009; 122:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/21\">",
"      Newman AB, Foster G, Givelber R, et al. Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch Intern Med 2005; 165:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/22\">",
"      Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/23\">",
"      Pillar G, Peled R, Lavie P. Recurrence of sleep apnea without concomitant weight increase 7.5 years after weight reduction surgery. Chest 1994; 106:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/24\">",
"      Bray GA. Barriers to the treatment of obesity. Ann Intern Med 1991; 115:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/25\">",
"      Kajaste, S, Telakivi, T, Pihl, S, Partinen, M. Effects of a weight reduction program on sleep apnea: A two year follow-up. Sleep Res 1991; 20A:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/26\">",
"      Kline CE, Crowley EP, Ewing GB, et al. The effect of exercise training on obstructive sleep apnea and sleep quality: a randomized controlled trial. Sleep 2011; 34:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/27\">",
"      Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006; 29:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/28\">",
"      Jokic R, Klimaszewski A, Crossley M, et al. Positional treatment vs continuous positive airway pressure in patients with positional obstructive sleep apnea syndrome. Chest 1999; 115:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/29\">",
"      Cartwright R, Ristanovic R, Diaz F, et al. A comparative study of treatments for positional sleep apnea. Sleep 1991; 14:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/30\">",
"      Bignold JJ, Deans-Costi G, Goldsworthy MR, et al. Poor long-term patient compliance with the tennis ball technique for treating positional obstructive sleep apnea. J Clin Sleep Med 2009; 5:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/31\">",
"      Issa FG, Sullivan CE. Alcohol, snoring and sleep apnea. J Neurol Neurosurg Psychiatry 1982; 45:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/32\">",
"      Aurora RN, Casey KR, Kristo D, et al. Practice parameters for the surgical modifications of the upper airway for obstructive sleep apnea in adults. Sleep 2010; 33:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/33\">",
"      Reeves-Hoch&eacute; MK, Hudgel DW, Meck R, et al. Continuous versus bilevel positive airway pressure for obstructive sleep apnea. Am J Respir Crit Care Med 1995; 151:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/34\">",
"      Nussbaumer Y, Bloch KE, Genser T, Thurnheer R. Equivalence of autoadjusted and constant continuous positive airway pressure in home treatment of sleep apnea. Chest 2006; 129:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/35\">",
"      Fietze I, Glos M, Moebus I, et al. Automatic pressure titration with APAP is as effective as manual titration with CPAP in patients with obstructive sleep apnea. Respiration 2007; 74:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/36\">",
"      Berry RB, Kryger MH, Massie CA. A novel nasal expiratory positive airway pressure (EPAP) device for the treatment of obstructive sleep apnea: a randomized controlled trial. Sleep 2011; 34:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/37\">",
"      Kryger MH, Berry RB, Massie CA. Long-term use of a nasal expiratory positive airway pressure (EPAP) device as a treatment for obstructive sleep apnea (OSA). J Clin Sleep Med 2011; 7:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/38\">",
"      McDaid C, Dur&eacute;e KH, Griffin SC, et al. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome. Sleep Med Rev 2009; 13:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/39\">",
"      Sharma SK, Agrawal S, Damodaran D, et al. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med 2011; 365:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/40\">",
"      Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I, et al. Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: a cohort study. Ann Intern Med 2012; 156:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/41\">",
"      Campos-Rodriguez F, Pe&ntilde;a-Gri&ntilde;an N, Reyes-Nu&ntilde;ez N, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. Chest 2005; 128:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/42\">",
"      Marti S, Sampol G, Mu&ntilde;oz X, et al. Mortality in severe sleep apnoea/hypopnoea syndrome patients: impact of treatment. Eur Respir J 2002; 20:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/43\">",
"      Waldhorn RE, Herrick TW, Nguyen MC, et al. Long-term compliance with nasal continuous positive airway pressure therapy of obstructive sleep apnea. Chest 1990; 97:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/44\">",
"      Rolfe I, Olson LG, Saunders NA. Long-term acceptance of continuous positive airway pressure in obstructive sleep apnea. Am Rev Respir Dis 1991; 144:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/45\">",
"      Hoffstein V, Viner S, Mateika S, Conway J. Treatment of obstructive sleep apnea with nasal continuous positive airway pressure. Patient compliance, perception of benefits, and side effects. Am Rev Respir Dis 1992; 145:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/46\">",
"      Krieger J, Kurtz D. Objective measurement of compliance with nasal CPAP treatment for obstructive sleep apnoea syndrome. Eur Respir J 1988; 1:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/47\">",
"      Meurice JC, Dore P, Paquereau J, et al. Predictive factors of long-term compliance with nasal continuous positive airway pressure treatment in sleep apnea syndrome. Chest 1994; 105:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/48\">",
"      Reeves-Hoche MK, Meck R, Zwillich CW. Nasal CPAP: an objective evaluation of patient compliance. Am J Respir Crit Care Med 1994; 149:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/49\">",
"      Kribbs NB, Pack AI, Kline LR, et al. Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 1993; 147:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/50\">",
"      Loube DI, Gay PC, Strohl KP, et al. Indications for positive airway pressure treatment of adult obstructive sleep apnea patients: a consensus statement. Chest 1999; 115:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/51\">",
"      Khan A, Ramar K, Maddirala S, et al. Uvulopalatopharyngoplasty in the management of obstructive sleep apnea: the mayo clinic experience. Mayo Clin Proc 2009; 84:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/52\">",
"      Mortimore IL, Bradley PA, Murray JA, Douglas NJ. Uvulopalatopharyngoplasty may compromise nasal CPAP therapy in sleep apnea syndrome. Am J Respir Crit Care Med 1996; 154:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/53\">",
"      Choi JH, Kim SN, Cho JH. Efficacy of the Pillar implant in the treatment of snoring and mild-to-moderate obstructive sleep apnea: a meta-analysis. Laryngoscope 2013; 123:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/54\">",
"      Caples SM, Rowley JA, Prinsell JR, et al. Surgical modifications of the upper airway for obstructive sleep apnea in adults: a systematic review and meta-analysis. Sleep 2010; 33:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/55\">",
"      Sundaram S, Bridgman SA, Lim J, Lasserson TJ. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev 2005; :CD001004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/56\">",
"      Lojander J, Maasilta P, Partinen M, et al. Nasal-CPAP, surgery, and conservative management for treatment of obstructive sleep apnea syndrome. A randomized study. Chest 1996; 110:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/57\">",
"      Woodson BT, Steward DL, Weaver EM, Javaheri S. A randomized trial of temperature-controlled radiofrequency, continuous positive airway pressure, and placebo for obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg 2003; 128:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/58\">",
"      Brown DJ, Kerr P, Kryger M. Radiofrequency tissue reduction of the palate in patients with moderate sleep-disordered breathing. J Otolaryngol 2001; 30:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/59\">",
"      Woodson BT, Nelson L, Mickelson S, et al. A multi-institutional study of radiofrequency volumetric tissue reduction for OSAS. Otolaryngol Head Neck Surg 2001; 125:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/60\">",
"      Pazos G, Mair EA. Complications of radiofrequency ablation in the treatment of sleep-disordered breathing. Otolaryngol Head Neck Surg 2001; 125:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/61\">",
"      Terris DJ, Chen V. Occult mucosal injuries with radiofrequency ablation of the palate. Otolaryngol Head Neck Surg 2001; 125:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/62\">",
"      V&auml;rendh M, Berg S, Andersson M. Long-term follow-up of patients operated with Uvulopalatopharyngoplasty from 1985 to 1991. Respir Med 2012; 106:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/63\">",
"      Browaldh N, Friberg D, Svanborg E, Nerfeldt P. 15-year efficacy of uvulopalatopharyngoplasty based on objective and subjective data. Acta Otolaryngol 2011; 131:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/48/2826/abstract/64\">",
"      R&ouml;&ouml;sli C, Schneider S, H&auml;usler R. Long-term results and complications following uvulopalatopharyngoplasty in 116 consecutive patients. Eur Arch Otorhinolaryngol 2006; 263:754.",
"     </a>",
"    </li>",
"    <li>",
"     Somers, V, Javaheri, S. Heart failure and arrhythmias in Obstructive Sleep Apnea. In: Principles and Practice of Sleep Medicine, 4th ed, Kryger, MH, Roth, T, Dement, WC (Eds), Saunders, Philadelphia 2005.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7695 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-7C479FB97E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2826=[""].join("\n");
var outline_f2_48_2826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Choosing a therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BEHAVIOR MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10842335\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sleep position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Alcohol avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Medication selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OSA-SPECIFIC THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Positive airway pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oral appliances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pharmacologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Comparisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Airway pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Oral devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Persistent sleepiness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7695\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7695|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/58/26541\" title=\"algorithm 1\">",
"      OSA treatment algorithm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=related_link\">",
"      Adherence with continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=related_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/6/8294?source=related_link\">",
"      Liabilities of sleep deprivation and sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/42/1704?source=related_link\">",
"      Oral appliances in the treatment of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/4/38978?source=related_link\">",
"      Patient information: Daytime sleepiness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/25/26003?source=related_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/51/38710?source=related_link\">",
"      Performance and safety risks of sleep deprivation and sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/45/3801?source=related_link\">",
"      Pharmacologic treatment of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17127?source=related_link\">",
"      The effects of medications on sleep quality and sleep architecture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_48_2827="Red eye that needs referral";
var content_f2_48_2827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Red eyes that must be referred emergently or urgently",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Angle closure glaucoma",
"       </td>",
"       <td>",
"        Emergent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyphema",
"       </td>",
"       <td>",
"        Emergent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypopyon",
"       </td>",
"       <td>",
"        Emergent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iritis",
"       </td>",
"       <td>",
"        Urgent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Infectious keratitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial&nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        Emergent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral",
"       </td>",
"       <td class=\"sublist_other\">",
"        Urgent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2827=[""].join("\n");
var outline_f2_48_2827=null;
var title_f2_48_2828="GOLD COPD Table 2";
var content_f2_48_2828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Table 2. Classification of severity*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        0: At Risk",
"       </td>",
"       <td>",
"        Normal spirometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic symptoms (cough, sputum production)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        I: Mild COPD",
"       </td>",
"       <td>",
"        FEV1/FVC &lt;70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FEV1 &ge;80 percent predicted with or without chronic symptoms (cough, sputum production)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        II: Moderate COPD",
"       </td>",
"       <td>",
"        FEV1/FVC &lt;70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 percent &le;FEV1 &lt;80 percent predicted with or without chronic symptoms (cough, sputum production)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        III: Severe COPD",
"       </td>",
"       <td>",
"        FEV1/FVC &lt;70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30 percent &le;FEV1 &lt;50 percent predicted with or without chronic symptoms (cough, sputum production)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        IV: Very Severe COPD",
"       </td>",
"       <td>",
"        FEV1/FVC &lt;70 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FEV1 &lt;30 percent predicted or FEV1&lt;50 percent predicted plus chronic respiratory failure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FEV1: forced expiratory volume in one second; FVC: forced vital capacity; respiratory failure: arterial partial pressure of oxygen (PaO2) less than 8.0 kPa (60 mm Hg) with or without arterial partial pressure of CO2 (PaCO2) greater than 6.7 kPa (50 mm Hg) while breathing air at sea level.",
"     <br>",
"      * Classification based on postbronchodilator FEV1.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: Executive Summary (Updated 2005). Reproduced with permission from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), file://www.goldcopd.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2828=[""].join("\n");
var outline_f2_48_2828=null;
var title_f2_48_2829="Morbidity in IDM";
var content_f2_48_2829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Perinatal mortality and neonatal morbidity in infants of diabetic mothers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rate, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal mortality",
"       </td>",
"       <td>",
"        0.6-4.8",
"       </td>",
"       <td>",
"        Lowest rates reflect very good prenatal care and strict glycemic control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cesarean delivery",
"       </td>",
"       <td>",
"        32-45",
"       </td>",
"       <td>",
"        Highest rates are associated with lowest perinatal mortality",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Prematurity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &lt;37 weeks gestation",
"       </td>",
"       <td class=\"sublist_other\">",
"        24-36",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &lt;34 weeks gestation",
"       </td>",
"       <td class=\"sublist_other\">",
"        14-16",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital anomalies",
"       </td>",
"       <td>",
"        1.7-9.4",
"       </td>",
"       <td>",
"        Lowest rates are associated with strict glycemic control preconception and in early pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal asphyxia, including fetal distress during labor, low 1-minute Apgar score, and intrauterine death",
"       </td>",
"       <td>",
"        9-27",
"       </td>",
"       <td>",
"        Lowest rates are seen with close monitoring during labor and appropriate intervention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macrosomia",
"       </td>",
"       <td>",
"        9-47",
"       </td>",
"       <td>",
"        Lowest rates are seen with strict glycemic control during pregnancy; strong association with neonatal hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrauterine growth restriction",
"       </td>",
"       <td>",
"        2-8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory distress syndrome",
"       </td>",
"       <td>",
"        2-6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"       <td>",
"        5-25",
"       </td>",
"       <td>",
"        Strong correlation with macrosomia, lower rates seen with strict glycemic control during pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypocalcemia",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Mostly asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycythemia (hematocrit &gt;65 percent)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperbilirubinemia",
"       </td>",
"       <td>",
"        11-29",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Symptomatic",
"       </td>",
"       <td class=\"sublist_other\">",
"        5-10",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asymptomatic",
"       </td>",
"       <td class=\"sublist_other\">",
"        30-50",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: The wide range cited for some complications is due to the inclusion of several studies, which were performed at different times, places in the world, and in different study groups (infants of all diabetic mothers, or those of gestational diabetic mothers or pregestational type 1 or 2 diabetic mothers). In many cases, different definitions of symptoms or findings were also used. In general, the lowest rates of complications are associated with improved obstetric care that resulted in better maternal glycemic control and neonatal management.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2829=[""].join("\n");
var outline_f2_48_2829=null;
var title_f2_48_2830="Causes of long QT syndrome";
var content_f2_48_2830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some reported causes and potentiators of the long QT syndrome*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Congenital",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Jervell and Lange-Nielsen syndrome (including \"channelopathies\")",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Romano-Ward syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acquired",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Metabolic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypokalemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypomagnesemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypocalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Starvation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anorexia nervosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Liquid protein diets",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypothyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bradyarrhythmias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sinus node dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            AV block - second or third degree",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antiarrhythmic drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quinidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Procainamide or N-acetylprocainamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Disopyramide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amiodarone and dronedarone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sotalol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dofetilide, ibutilide, azimilide, sematilide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antimicrobial drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Erythromycin, clarithromycin, telithromycin, azithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pentamidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Some azole antifungals - voriconazole, posaconazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Some fluoroquinolones (eg, sparfloxacin, gatifloxacin, levofloxacin, moxifloxacin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Other - spiramycin, chloroquine, halofantrine mefloquine",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Acquired (continued)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antihistamines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Terfenadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Astemizole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Psychotropic drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thioridazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Phenothiazines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tricyclic or tetracyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Haloperidol and other butyrophenones",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Antineoplastic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Crizotinib, dasatinib, eribulin, nilotinib, romidepsin, sorafenib, sunitinib, vandetanib, vemurafenib, vorinostat",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Selective serotonin reuptake inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Risperidone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Opioids (methadone, oxycodone)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Vasodilators - prenylamine, bepridil, mibefradil",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diuretics - via electrolyte changes (esp. hypokalemia or hypomagnesemia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            5HT3-antagonists - ondansetron, granisetron, and dolasetron",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Motility drugs - cisapride, domperidone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Droperidol - may be safe at the low doses used by anesthesiologists (0.625 to 1.25 mg)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ranolazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            HIV protease inhibitors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Miscellaneous - organophosphate insecticides, probucol, cocaine, terodiline, papaverine, certain Chinese herbs, chloral hydrate, arsenic trioxide, cesium chloride, levomethadyl",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other factors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Myocardial ischemia or infarction, esp. with prominent T wave inversions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Intracranial disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            HIV infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypothermia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Connective tissue diseases with anti-Ro/SSA antibodies",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The long and growing list of medications and other factors capable of prolonging the QT(U) represents an evolving area of clinical research. In some cases of long QT-U two or more factors may be involved. Additional clinical information is provided at the Arizona Center for Education and Research on Therapeutics (CERT) website:",
"     <a href=\"file://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm\" target=\"_blank\">",
"      file://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm",
"     </a>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2830=[""].join("\n");
var outline_f2_48_2830=null;
var title_f2_48_2831="Trichuriasis rectal prolapse";
var content_f2_48_2831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trichuriasis rectal prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 292px; height: 192px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rectal prolapse due to trichuriasis. White adult worms can be seen on the surface of the mucosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From the collection of Herman Zaiman, \"A Presentation of Pictorial Parasites.\" Reproduced with permission from: the American Society of Tropical Medicine and Hygiene.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_48_2831=[""].join("\n");
var outline_f2_48_2831=null;
           